Login
Oncologisch onderzoek.nl
Home
Login
Links
Contact
Registreren
Jarig
Nieuws
1
2
3
4
5
25
50
250
500
>
>>
Pagina 1/ 700 - 15 Lijnen per pagina - 10497 Lijnen in deze sectie
Titel
Commentaren
Datum
Auteur
AML: geen depletie maar differentiatieremming van hematopoëtische stamcellen
(0)
2013-08-15 20:53
dr. Jan Blom
Aneuploïdie drijvende kracht bij evolutie van kanker
(0)
2013-11-02 20:56
dr. Jan Blom
Alternatieve VEGF-liganden bij resistentie mCRC tegen anti-VEGF therapie
(0)
2013-11-01 20:42
dr. Jan Blom
Nieuw werkingsmechanisme PTEN ontdekt
(0)
2013-07-31 20:59
dr. Jan Blom
Atypisch leeftijds-specifiek patroon HCC in Peru
(1)
2013-09-03 21:05
dr. Jan Blom
Pijn en pijn-interferentie in lange-termijn overlevers van maligniteiten tijdens de jeugd
(0)
2020-04-01 13:41
Hypomethylerende middelen voor hoog-risico MDS of AML: risico van invasieve schimmelinfecties
(0)
2020-04-06 11:52
Fase 3-studie van eerstelijns durvalumab met of zonder tremelimumab versus chemotherapie voor mNSCLC
(0)
2020-04-11 15:00
Associatie tussen onverwacht gewichtsverlies en diagnose van een maligniteit in de eerstelijns zorg
(0)
2020-04-16 15:00
Detectie van SARS-COV2 antilichamen na symptomatisch COVID-19 in patiënten met maligniteiten
(0)
2020-05-03 12:00
Lange-termijn resultaten van lenalidomide-bortezomib-dexamethason inductie en risico-aangepast onderhoud voor NDMM
(0)
2020-04-18 13:28
Voorspelling van mortaliteit aan maligniteiten in 2020 in de Europese Unie
(0)
2020-04-20 11:46
Chirurgie met of zonder perioperatieve radiotherapie voor extrameningeale solitaire fibreuze tumoren
(0)
2020-04-22 11:42
Uitkomsten van standaardbehandelingen en immuuncheckpointremming voor CDK12-gemuteerd prostaatcarcinoom
(0)
2020-04-22 13:01
Toevoegen van ramucirumab aan docetaxel na anti-PD-1/PD-L1 behandeling voor NSCLC
(0)
2020-04-27 13:00
1
2
3
4
5
25
50
250
500
>
>>
Pagina 1/ 700 - 15 Lijnen per pagina - 10497 Lijnen in deze sectie
Tags
'gunstig hoog-risico'
“one thousand HER2 patients” project
(chemo)endocrine therapy
[11C] docetaxel
[18F]paclitaxel
%FT
1-day multidisciplinary clinic
1-year versus shorter duration of adjuvant trastuzumab
10-year outcomes
10-year recurrence
15-hydroxyprostaglandinedehydrogenase
15-PGDH
16K PRIL
16q23
1703-studie
18F-FDG opname
1990 to 2017
1990-2017
1997-2016
1p 19q co-deleted oligodendroglioma
1p 19q codeleted oligodendroglioma
20-year follow-up
2003-2007 versus 2013-2017
2006-2016
2010-2016
2018 FIGO stage IIIC SCC of the cervix
2021 cancer mortality prediction in EU and UK
21-gen recurrence score assay
21-gene assay and breast cancer mortality
21-gene assay recurrence score
21-gene expression assay
21-gene recurrence score
21-gene recurrence score and BCSS
21-gene RS and response to neoadjuvant chemotherapy
25-hydroxyvitamin D
25-OH-D level at time of diagnosis
27-hydroxycholesterol
28-year risk of lung cancer
3 versus 1 year adjuvant imatinib
3 versus 6 months adjuvant chemotherapy
3 vs. 6 months oxaliplatin-based adjuvant chemotherapy
321GO
3D brachytherapy
3DCRT
4 Gy versus 24 Gy radiotherapy
45 and Up Study
4EVER trial
4L lymph node dissection
5-ARIs
5-fraction whole-breast radiotherapy
5-FU
5α-reductase inhibitors
6-MP plus methotrexate
70-GS
8-OHdG
90101 CREATE-studie
90YIT
91-maands update van CALGB 100104-studie
A.R.R.O.W-studie
A041202 study
AAC
AACR
AACR 2015
AACR Academy
AAML0531 trial
AAML1421 study
AAP
abatacept for prevention of acute GVHD
ABCB1 genetic variants
ABCSG 8A trial
ABCSG-18 study
abdominal and gluteofemoral size
abdominal radiation for childhood cancer; subsequent risk of diabetes
abemaciclib
abemaciclib plus fulvestrant for MBC
Abi Race studie
abirateron
abiraterone
abiraterone for prostate cancer
ablatieve behandeling
ablative therapy after TACE for HCC
abnormale peritoneale cytologie
ABOUND.2L+ study
ABP plus gemcitabine
abscopal effect
ABSI
ABSOLUTE
absolute dense area
absoluut neutrofielgetal
ABT-199
ABTC
ABVD
ABVD versus BEACOPP-escalated
acalabrutinib
acalabrutinib monotherapy
ACC
accelerated cellular senescence after chemotherapy
accelerated partial breast irradiation
ACCENT database analysis
access to anticancer medicines for children and adolescents in Europe
ACCRU study SC-1603
accrual
ACE
ACE inhibitors versus ARBs
ACE study
ACE-LY-004 studie
ACES
acetaminophen
ACHIEVE study
acid-suppressive medication
acne
ACOSOG Z0011
ACP statement
acquired resistance to osimertinib
acraal melanoom
ACRIN 6686-studie
acromegaly
AcSé phase 2 study
AcSé study
ACT
ACT-2 trial
Act.In.Sarc study
actieve surveillance
ACTIM
actinic keratosis
actinisch carcinoom
active melanoma brain metastases
active surveillance
active surveillance for low-risk prostate cancer
active surveillance for prostate cancer
activering immuunsysteem
ACTs
acupuncture for aromatase inhibitor-related joint pain
acute cancer-associated venous thromboembolism
acute care use after initiation of systemic cancer therapy
acute graft-versus-host disease
acute GVHD
acute kidney injury
acute leukemia
acute leukemie
acute lymfoblastische leukemie
acute lymphoblastic leukemia
acute myeloid leukemia
acute myeloïde leukemie
acute promyelocytische leukemie
acute promyeolcytische leukemie
acute toxicity
AD-risico
adagrasib
ADAM-studie
ADAM8
ADAMTS-mutaties
ADAPT-studie
adaptive immune resistance
adaptive randomization
ADAURA study
adavosertib
ADC as response marker
ADC versus SCC
ADCs
adding durvalumab and olaparib to chemotherapy
adding gemcitabine to adjuvant chemotherapy
adding MRI and biomarkers
adding OFS to tamoxifen
addition of adjuvant capecitabine to standard chemotherapy
addition of androgen deprivation therapy or brachytherapy boost
addition of arsenic trioxide to frontline treatment
addition of bortezomib to melphalan and dexamethasone
addition of carboplatin to neoadjuvant chemotherapy
addition of chemotherapy to local therapy
addition of chemotherapy to neoadjuvant radiotherapy
addition of concurrent hypo-fractionated RT to failing anti-PD-1 therapy
addition of COX inhibition to immune checkpoint blockade
addition of daratumumab to lenalidomide plus dexamethasone
addition of lenalidomide to R-CHOP
addition of ramucirumab to docetaxel
additional cytogenetic abnormalities
additional immune modulators
ADEBAR
ademanalyse
ademtest
adenocarcinoma of the small intestine
adenocarcinoom
adenoma detection rate
ADH
adherence
adherene to adjuvant endocrine therapy
adherentie
adherentie AET
adherentie orale chemotherapie
adipose tissue distribution
adipositas
adiposity and survival
adjuvant abemaciclib plus endocrine treatment
adjuvant aromatase inhibitor
adjuvant aspirin for cancer
adjuvant bevacizumab
adjuvant capecitabine
adjuvant carboplatin plus taxanes versus EC followed by taxanes
adjuvant care
adjuvant chemotherapy
adjuvant chemotherapy after pCR to neoadjuvant CRT
adjuvant chemotherapy for breast cancer
adjuvant chemotherapy regimens
adjuvant CRT
adjuvant dabrafenib plus trametinib for stage III melanoma
adjuvant dabrafenib plus trametinib versus placebo for BRAF V600-mutated stage III melanoma
adjuvant denosumab
adjuvant docetaxel-based chemotherapy for early breast cancer
adjuvant endocrine therapy
adjuvant erlotinib for early-stage NSCLC
adjuvant ET ± CT
adjuvant ET with or without abemaciclib
adjuvant etoposide plus cisplatin
adjuvant FOLFIRINOX versus gemcitabine
adjuvant FOLFOX FLOX
adjuvant gefitinib versus chemotherapy
adjuvant imatinib
adjuvant ipilimumab
adjuvant ipilimumab versus IFNα-2b
adjuvant multimodality therapy
adjuvant nivolumab vs ipilimumab
adjuvant osimertinib
adjuvant paclitaxel and carboplatin versus CEF-T
adjuvant pemetrexed plus cisplatin versus vinorelbine plus cisplatin
adjuvant radiation
adjuvant radiation therapy
adjuvant radiotherapy
adjuvant RT
adjuvant RT for breast cancer
adjuvant S-1
adjuvant S-1 plus endocrine therapy
adjuvant S-1 with or without docetaxel
adjuvant SCRT versus CCRT or RT alone
adjuvant sorafenib
adjuvant therapy
adjuvant transarterial FOLFOX infusion
adjuvant trastuzumab
adjuvant trastuzumab duration
adjuvant trastuzumab for HER2-positive breast cancer
adjuvant treatment
adjuvant treatment for breast cancer
adjuvant treatments
adjuvant versus early salvage radiotherapy after prostatectomy for prostate cancer
adjuvant versus salvage radiotherapy
adjuvant weekly docetaxel plus radiotherapy
adjuvant XT-XEC versus T-FEC
ADJUVANT-studie
adjuvante chemotherapie
adjuvante CRT
adjuvante HER2-remming
adjuvante hormoontherapie
adjuvante systemische therapie
adjvant trastuzumab with or without chemotherapy
adjvuant chemotherapy versus chemoradiotherapy
ADMIRAL study
ADMIRAL trial
ADNEX
ado-trastuzumab emtansine
adolescent and young adult
adolescent and young adult cancer survivors
adolescent and young adult HL
adolescent overweigh or obesity
adolescents and young adults
adoptive T-cell therapy
ADORE trial
ADR
adrenocortical carcinoma
ADT
ADT for prostate cancer
ADT risk of depression
adult alternative donor HCT
adult cancers
adult glioma
adult glioma risk
adult height
adult survivors of childhood ALL
adult survivors of childhood cancer
adult survivors of childhood cancer diagnosed between 1970 and 1999
adult survivors of neuroblastoma
adult T-cell leukemia lymphoma
adult type granulosa cell tumors of the ovary
adult weight gain
advanced adrenocortical carcinoma
advanced ALK-positive NSCLC
advanced ALK-positive or ROS1-positive NSCLC
advanced anal cancer
advanced anal squamous cell carcinoma
advanced anthracycline-naive sarcoma
advanced B-RAF- or K-RAS N-RAS-mutated solid tumors
advanced biliary tract cancer
advanced biliary tract cancers
advanced BRAF-mutated melanoma
advanced BRAF-V600 mutated melanoma
advanced breast cancer
advanced BTC
advanced cancer
advanced cancer-related chronic nausea and vomiting
advanced cancers
advanced carcinoid or pancreatic neuroendocrine tumor
advanced ccRCC
advanced chondrosarcoma
advanced chordoma
advanced CLDN18.2 positive gastric cancer
advanced clear cell RCC
advanced colorectal liver metastases
advanced CRPC
advanced EGFR-positive non-squamous NSCLC
advanced endometrial cancer
advanced epithelial ovarian cancer
advanced epithelioid sarcoma with loss of INI1 SMARCB1
advanced esophageal cancer
advanced esophageal squamous cell carcinoma
advanced esophagogastric cancer
advanced extraskeletal myxoid chondrosarcoma
advanced G GEJ cancer
advanced gastric cancer
advanced gastric or colorectal cancer
advanced gastric or gastroesophageal junction cancer
advanced gastroesophageal cancer
advanced gastrointestinal cancer
advanced gastrointestinal stromal tumors
advanced germ cell tumors
advanced GIST with KIT or PDGFRA mutation
advanced HCC
advanced hepatocellu;ar carcinoma
advanced hepatocellular carcinoma
advanced hepatocellular carcinoma after progression on anti-PD-(L)1
advanced HL with large nodal mass
advanced HN CSCC
advanced HNSCC
advanced Hodgkin lymphoma
advanced HR-positive breast cancer
advanced indolent lymphoma
advanced leiomyosarcoma liposarcoma
advanced liver cancer
advanced lung cancer
advanced melanoma
advanced melanoma in patients not represented in phase 3 trials
advanced Merkel cell carcinoma
advanced microsatellite instability-high cancers
advanced mucosal melanoma
advanced non-clear cell RCC
advanced non-clear-cell RCC
advanced non-small cell lung cancer
advanced non-squamous NSCLC
advanced nonsquamous non-small cell lung cancer
advanced nonsquamous NSCLC
advanced nonsquamous NSCLC in elderly patients
advanced NSCLC
advanced NSCLC harboring KRAS G12C mutation
advanced NSCLC in special populations
advanced NSCLC with T790M mutated EGFR
advanced or metaastatic colorectal cancer
advanced or metastatic colorectal cancer
advanced or metastatic CRC
advanced or metastatic thymic carcinoma
advanced or metastatic urothelial carcinoma
advanced or recurrent endometrioid endometrial cancer
advanced or refractory desmoid tumors
advanced ovarian cancer
advanced ovarian carcinoma
advanced ovarium neoplasms
advanced pancreatic cancer
advanced papillary renal cell carcinoma
advanced PDAC
advanced prostate cancer
advanced pulmonary sarcomatoid carcinoma
advanced rare cancers
advanced rare genitourinary malignancies
advanced RCC
advanced recurrent ovarian cancer
advanced refractory biliary tract cancer
advanced refractory CRC
advanced refractory esophageal squamous cell carcinoma
advanced renal cell carcinoma
advanced salivary gland carcinoma
advanced sarcoma
advanced soft-tissue sarcoma
advanced solid cancers
advanced solid HER2-positive tumors
advanced solid malignancies
advanced solid tumors
advanced solid tumors with KRAS-G12C mutation
advanced squamous non-small cell lung cancer
advanced squamous NSCLC
advanced stage iNHL
advanced STS
advanced systemic mastocytosis
advanced thymoma
advanced triple-negative breast cancer
advanced UC
advanced urological cancers with pre-existing autoimmune disorders
advanced urothelial cancer
advanced urothelial carcinoma
advanced USC with HER2 overexpression
advanced wild-type BRAF melanoma
advanced-stage cancer
advanced-stage Hodgkin lymphoma
advanced-stage Hodgkin’s lymphoma
Adventist cohort compared with a US Census popiulation
adverse events
adverse mental health outcomes
ADVL1412 study
aerobe inspanning
aerobic and resistance exercise
aerobic exercise during chemotherapy
afatinib
afatinib versus methotrexaat
AFFIRM
AFFIRM-studie
aflibercept
AFUGEM GERCOR
AGC
age
age at diagnosis
age at diagnosis of colorectal cancer
age dependence of modern clinical risk groups
age disparities
age-specific BMI
agent orange
AGES-Reykjavik study
aggressive lymphoma
aggressive prostate cancer
aggressive versus non-aggressive prostate cancer
AGITG MAX study
AGO-OVAR 16-studie
agressieve fibromatose
agressive squamous cell carcinoma
AGRICAN-studie
aGVHD
aHCC
AHEP0731 study
AHL2011 study
AHOD1221 study
AI
AI-induced arthralgia
AI-therapie
AIC
AIO-FLOT3 studie
AJCC 8th edition stage III melanoma
AJCC CSM-8
AL amyloidosis
AL-amyloïdose
ALBI
ALCANZA-studie
ALCL
aLCNEC
alcohol
alcohol and tobacco consumption
alcohol consumption
alcohol consumption and cancer risk in Australia
alcohol intake
alcoholconsumptie
alcoholgebruik
ALCYONE trial OS analysis
ALCYONE-studie
aldoxorubicine
alectinib
alectinib for crizotinib-resistant ALK-positive NSCLC
alectinib versus crizotinib
ALEX study
ALEX study PRO analysis
ALEX-studie
ALFA-0701 trial
ALFA0701 trial
ALiCCS studie
ALiCCS study
ALiCCS-studie
alisertib
alisertib plus induction chemotherapy
ALK inhibitors for NSCLC with ALK-rearrangement
ALK-positive non-small cell lung cancer
ALK-positive NSCLC
ALK-rearranged NSCLC
ALK-remmer
ALK(+) and ROS1(+) NSCLC
ALK1
alkaline phosphatase
alkylerende chemotherapie
ALL
all-cause and cardiovascular disease mortality
Alliance A091401-studie
Alliance N0572-studie
ALLIVE-studie
allo-BMT
allo-HSCT
allo-HST
allogene hematopoïetische stamceltransplantatie
allogene stamceltransplantatie
allogeneic BMT in childhood
allogeneic hematopietic cell transplantation
allogeneic hematopoietic cell transplant
allogeneic hematopoietic cell transplantation
allogeneic hematopoietic cell transplantation outcomes
allogeneic HSCT
allogeneic stem cell transplantation for AML or ALL
allogeneic stem cell transplantion
allogeneic transplantation for myelodysplastic syndrome
allogenic transplant for NHL
alloHCT
alloHCT for myelofibrosis
alloHCT recipients
alloHSCT
alloHSCT for pediatric ALL
alloHSCT in women
alloSCT
almonertinib
ALND
alopecie
alpelisib
alpelisib plus fulvestrant
alpelisib plus nab-paclitaxel
alpha-fetoprotein
ALTA-1L
ALTA-1L second interim analysis
ALTA-studie
ALTER 0303 study
alternative cisplatin schedule
ALTERNATIVE study updated results
ALTERNATIVE-studie
ALTTO study sub-analysis
ALUR-studie
alveolar soft-part sarcoma
alvleesklierkanker
AM
Amara West
AMATERASU trial subgroup analysis
AMD
American Association for Cancer Research
American Cancer Society richtljnen
AMG 337
AMH
AML
AML in elderly nonfit patients
AML MDS
AML MDS in older patients
AML or high-risk MDS
AML with FLT3-ITD mutation
AML with genomic evidence of residual disease
AML with internal tandem duplication of Fms-like tyrosine kinase 3
AML-relapse after allo-HCT
AML-risico
AML17-studie
AMLSG 09-09 study
AMPK variant
AMPK-route
AMPLE-2 study
amrubicine
analgesic use
analgesics
analgetica
analyse AZURE-studie
analyse binnen PICCOLO-studie
analyse CheckMate 205-studie
analyse COG AAML 1031
analyse CROSS-studie
analyse fase 3-studie CALGB 40503
analyse fase 3-studie GeparQuinto
analyse MA.27-studie
analyse NORDIC-VII studie
analyse STAMPEDE-studie
Analyse van CheckMate 066 en CheckMate 067
analyse van fase 3-studie CAO ARO AIO-04
analyse van STAMPEDE-studie
anamorelin
anaplastic astrocytoma or glioblastoma
anaplastic large-cell lymphoma
anaplastic thyroid carcinoma
anaplastisch grootcellig lymfoom
anaplastisch schildkliercarcinoom
anastrazole with or without fulvestrant
anastrozol
anastrozole
and HIV infection
and rituximab
and time already survived
androgeendeprivatie
androgeenreceptor
androgeensuppressie
androgen concentrations in prepubertal girls
androgen deprivation for FIR versus UIR prostate cancer
androgen deprivation therapy
androgen deprivation therapy for prostate cancer
androgen receptor expression
androgen receptor signaling inhibitor
anesthesia
anetumab ravtansine
aneuploïdie
ANG1005
angiogenese
angiosarcomen
angiosarcoom
angiotensin converting enzyme inhibitors
angiotensin II receptor blockers
ANGPT2
ANGPT2 and NOS3 polymorphisms
animal and plant protein intake
anlotinib
anlotinib versus sunitinib
ANNOUNCE trial
anoikis-resistentie
anorexia nervosa
anorexie
anosmin-1
aNSCLC
aNSCLC with PD-L1 at least 50%
antacida
anterior temporal lobotomy
anthracycline chemotherapie
anthracyclines
anthracylcines
anti-angiogene middelen
anti-angiogenese
anti-B-cell maturation antigen BiTE molecule AMG 420
anti-CD19 and anti-BCMA CAR T-cells
anti-CD19 CAR T-cell therapy
anti-CD19 CAR T-cells
anti-CD22 CAR T-cells
anti-CD30 CAR-T cell therapy
anti-CTLA-4 plus anti-PD-1 blockade
anti-diarrheal strategies
anti-EGFR
anti-HER2 therapy
anti-HER2 therapy for MBC
anti-Hu
anti-humaan T-lymfocyt immunoglobuline
anti-PD-(L)1 therapy
anti-PD-1
anti-PD-1 antibodies plus RT
anti-PD-1 immunotherapy for MSS solid tumors
anti-PD-1 L1
anti-PD-1 monotherapy
anti-PD-1 related pneumonitis
anti-PD-1 therapy
anti-PD-1 therapy for advanced melanoma
anti-PD-1 therapy for solid tumors
anti-PD-1 vs anti-PD-L1 for cancer
anti-PD1 with or without anti-CTLA4
anti-programmed cell death 1 therapy
Anti-T-lymfocten globuline
anti-thymocyte globulin
anti-TNF for steroid refractory toxicity
anti-VEGF therapie
anti-VGEF therapie
antiangiogenese
antibiotic use and risk of colorectal cancer
antibiotics
antibodies
antibody-drug-conjugates
anticoagulants and breast cancer survival
anticoagulatie
antihypertensive drugs
antiogeneseresistentie
antioxidant supplements
antioxidanten
antioxidants
antithymocyte globulin
antithymocytenglobuline
antitumor-werkzaamheid van bisfosfonaten
antiviral treatment
anus squameus celcarcinoom
anuscarcinoom
anuskanker
AO AOA
apalutamide
apalutamide versus placebo for nmCRPC
apatinib
apatinib after failure of chemotherapy
apatinib plus oral etoposide
apatinib plus pemetrexed-platinum chemotherapy
APBI versus WBI
aPC
APHINITY trial 6-year follow-up
APHINITY-studie
API-AI
apixaban
APL
APL in older patients
APOLLO study
apoptose
appendixcarcinoom
aprepitant
APT trial
AR expression in breast cancer
AR-expression
AR-remming
AR-V7
ARAMIS study
ARCAD
ARCAD-NADEGE cohort study
ARCAGE-studie
aRCC
ARCHER 1050
ARCHER 1050-studie
ARCHES study
ARCTIC study
ARIC-studie
ARIEL3-studie
ARIs for prostate cancer
Aristotle study
ARMD
aRMS
aromatase inhibitors
aromatase inibitor-induced adverse effects
aromataseremmer
aromataseremmers
array comparative genomic hybridization
ARROW study
ARRY-380
arseentrioxide
arsenicum
ARST1321 study
ART
ART-gerichte behandeling
arterial thromboembolism preceding cancer diagnosis
artificial intelligence
artificial intelligence algorithms
ARTIS study
ARTIST 2 study
ARTIST 2 trial
artralgie
ARTSCAN III study
ARv567es
AS04-adjuvanted HPV-16 18 vaccine
ASCC
ASCEMBL study
ASCEND study
ASCEND-2
ASCEND-3 final results
ASCEND-5
ASCEND-5 studie
ASCENT study
asciminib
asciminib versus bosutinib
ascites
ASCO
ASCO 2016
ASCT
ASCT versus maintenance chemotherapy consolidation
ASH 2015
Ashkenazi Jewish ancestry
ASILs
asparaginase-associated pancreatitis
ASPECCT
AspECT study
ASPIRE-studie
aspirin
aspirin NSAID use
aspirin use
aspirin use and CRC risk in older adults
aspirine
aspirine NSAIDs
aspirineprofylaxe
ASPREE study
ASPS
assessment of lung cancer risk
assessment of screening mammograms
Assisted reproduction
assisted reproductive technology
associatie diabetes en kanker
association between Alzheimer disease and cancer
association between PFS and QOL
association between previous infection and cancer risk
association of adjuvant chemotherapy with overall survival
association of age with efficacy of immunotherapy
association of breast cancer risk with type 2 diabetes and metformin use
association of coffee intake and survival
association of ctDNA and CTCs after NAC with disease recurrence
association of cutaneous toxic effects with outcomes
association of depression and anxiety with mortality
association of fiber intake and breast cancer incidence
association of hearing impairment with neurocognition
association of HPV status with survival
association of intensity and duration of alcohol use and risk of head and neck cancer
association of measurable residual disease with DFS and OS
association of MHT with breast cancer subtypes
association of molecular characteristics with OS benefit
association of neoadjuvant chemotherapy with survival
association of obesity with outcomes of breast cancer subtypes
association of pCR with outcomes in breast cancer
association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors
association of performance status with survival
association of periodontal disease and edentulism with cancer mortality
association of physical activity with survival
association of procedure volume and in-house mortality
association of race and socioeconomic factors with OS
association of recent oncologic treatment with mortality
association of sarcopenia with short-term outcomes
association of time-to-treatment initiation and survival
association of use of PET-CT with mortality
association with cancer risk
association with hepatic malignancy
association with lung cancer risk
association with other types of tumors
association with survival
association with type of treatment
associations of irAEs with clinical outcomes
associations with prostate cancer risk
associations with season of birth
AST
astma
ASTRO 2015
ASTRO 2016
asunercept
asymptomatic brain metastases
asymptomatic early-stage CLL
asymptomatic mCRPC
asymptomatic WM
AT RT
ATBC Study
ATC
ATE
atezolizumab
atezolizumab for urothelial carcinoma
atezolizumab plus bevacizumab
atezolizumab plus nab-paclitaxel
atezolizumab with or without bevacizumab
atezolizumab-vemurafenib-cobimetinib
ATG
ATL
ATLANTIC-studie
ATM
ATM mutations in cancer
ATOM study
ATOM trial
atopic dermatitis
atopic eczema and cancer risk
atopie
ATR-blockers
atrial fibrillation
atriumfibrilleren
ATRTs
ATTRACTION-2 studie
ATTRACTION-3 study
atypical breast lesions
atypical bronchopulmonary carcinoids
atypical chronic myeloid leukemia
atypical squamous cell of undetermined signifance
atypical squamous cells of undetermined significance
atypisch meningioom
atypische ductale hyperplasie
atypische hyperplasie
Atypische teratoïde rhabdoïde tumor
atypische teratoïde rhabdoïde tumoren
AUGMENT study
AURA
AURA studies
AURA-studie
AURA-substudie
AURA2
AURA3
AURA3 overall survival analysis
AURA3 study
AURA3-studie
AURELIA
AURELIA-studie
AURELIA-substudie
Aurora A
aurora kinase A inhibition
Australian Melanoma Family Study
auto-immuunziekten
autofagie
autoHCT
autoHSCT
autoimmune disease
autologe stamceltransplantatie
autologous stem cell transplantation
AVAglio
avapritinib
AVAST-M study
AVAST-M trial
AVAST-M trial analysis
avastin
avelumab
avelumab maintenance
avelumab plus axitinib
avelumab versus chemotherapy maintenance
average risk B-ALL in children
AVERT study
AVERT trial
avoiding peg-filgrastim
avoiding unnessecary surgery
axi-cel
axi-cel in the non-trial setting
axicabtagene ciloleucel
axillaire lymfeklierdissectie
axillaire radiotherapie
axillaire status
axillaire ultrasound
axillary dissection
axillary surgery and nodal irradiation
axitinib
axitinib plus pembrolizumab
AYA cancer
AYA cancer survivors
AYA-maligniteiten
AYAs
AYAs versus older adults
AZ9291
azacitidine
AZD4547
B-cel activering
B-cel lymfoom
B-cel maligniteiten
B-cel precursor-ALL
B-cell ALL resistant to CD19 immunotherapy
B-cell lymphoma
B-cell malignancies
B-cell non-Hodgkin lymphoma
B-cellymfoom
B-precursos ALL
B-progenitor acute lymphoblastic leukemia
baarmoederhalskanker
BALLET-studie
BAP1 pathogenic variant carriers
bariatric surgery
bariatric surgery in French obese patients
bariatrische chirurgie
Barrett esophagus
Barrett slokdarm
Barrett-slokdarm
Barrett's esophagus
Barrett's slokdarm
Barrett’s oesophagus
basaalcelcarcinoom
basal-like mammacarcinoom
Baselga
baseline factors associated with response
baseline metabolic tumor volume as predictive and prognostic biomarker
basline plasma tumor mutational burden
bassi
BAT
BAY1436032
bb2121
BBB
BBD
BBD-BC
BCBM
BCC
BCCs
BCCSS
BCG
BCG vaccination in childhood
BCG-unresponsive non-muscle-invasive bladder cancer
BCIN+
BCIS
Bcl-2
BCL2 expression
BCMA-targeted CAR-T cell therapy for MM
BCNU
BCP-ALL
BCRA-mutated advanced breast cancer
BCS
BCS for N2 N3 disease
BCS versus mastectomy after neoadjuvant chemotherapy
BCT versus mastectomie
BCT vs MAST
BEACON CRC study
BEACON-studie subgroep-analyse
BEAT Cancer interventie
BEBYP-studie
Beckwith-Wiedemann syndrome
BECOME randomized trial
beeld-geleide brachytherapie
beeldvorming
beenmergevaluatie
beha
belangenconflicten
belantamab mafodotin
belinostat
BELIS study
BELLE-2 studie
BELLINI trial
BELOB
belotecan versus topotecan
bendamustine
bendamustine plus dexamethasone
benign biopsy rate
benign ovarian tumor
benign ovarian tumors
benign solid tumors
benigne borstziekte
benzeen
benzodiazepine
BEP
berberine versus placebo for the prevention of recurrence of colorectal adenoma
BERIL-1
bestraling
BET inhibitor RO6870810
beta-arrestin-1
BETA-Text
bètablokkers
between-hospital variation
bevaciumzab
bevacizumab
bevacizumab and platinum-based combinations
bevacizumab biosimilar
bevacizumab preconditionering voor chemotherapie
bevacizumab-resistant high-grade glioma
BEVZ92
BFORE-studie
BGJ398
bhatia
BI-ALCL
BIA ALCL
biallelic pathogenic CHEK2 variants
BIDOC-studie
BIG 1-01
BIG 1-98
BIG 1-98 trial analysis
bijnierschorscarcinoom
bijniertumoren
bijwerkingen
bilateral breast cancer
bilaterale risicoreducerende mastectomie
BILCAP study
BILCAP-studie
biliary tract cancer
BIND-014
Bing-Neel syndrome
binimetinib
bintrafusp alfa
biochemical recurrence of prostate cancer
biochemically detected nonadherence to adjuvant tamoxifen
biochemisch recidief
biologic subtype
biological aging
biological disease-modifying antirheumatic drugs
biologische beschikbaarheid
biomarker
biomarker voor respons op bevacizumab
biomarker-driven therapies
biomarkeranalyse ASPECCT-studie
biomarkers
biomarkers for nivolumab efficacy
biomarkers for surveillance
biomarkers of breast cancer risk
biomarkers of response to ICIs
biopsie schildwachtklier
bipolar androgen therapy
BIRC3 mutations
BIRCH-studie
birinapant
birth defects
birth order
BIS versus circumference assesements
bisfosfonaat
bisfosfonaten
bispecific CAR-T cell targeting both CD19 and CD22
bisphosphonates and risk of cancers
blaascarcinoom
blaaskanker
black race
black versus nonblack men
black versus white patients
black versus white women
Black Women's Health Study
Black Women’s Health Study
bladder cancer
bladder cancer in postmenopausal women
bladder cancer risk
bladder cancer VI-RADS score
BLC2001 study
bleeding after ACS
bleeding risk
BLEND study
bleomycin-related pulmonary toxicity
bleomycine
blinatumomab
blinded double reading
bloedgluocse
bloeding
bloedkanker
bloedlipiden
bloedtest colorectaalcarcinoom
blood arsenic levels
blood cholesterol
blood markers of oxidative stress
Blood or Marrow Transplant Survivor Study-2
blood pressure
blood tests
blood triglycerides
blood tumor mutational burden
blood-based test for the detection of multiple cancer types
bloodstream infections
BLOOM study
BLU-667
BM
BMD
BMI
BMI and outcomes of systemic therapy for metastatic melanoma
BMM
BMT
BMT CTN 1501 study
BO
body composition
body composition and cardiovascular events
body fat
body fat distribution
body fat mass
body fat percentage
body mass index
body shape trajectory
Boekel
BOLERO-1
BOLERO-2
bone loss in younger breast cancer patients
bone marrow biopsy
bone marrow plasma cell level
bone marrow versus blood stem cell graft
bone metabolism
bone metastases
bone modifying agents
bone sarcoma survivors
bone-metastatic castration-resistant prostate cancer
bone-only metastasis
bone-targeted agents
borderline ovarian tumor
borderline ovariumtumor
borderline resectable or locally advanced unresectable pancreatic cancer
borderline resectable pancreatic cancer
Borealis-1 studie
Borealis-2 studie
borstbiopsie
borstchirurgie
borstdichtheid
borstimplantaat
borstkanker
borstkanker bij mannen
borstkankerpreventie
borstkankerscreening
borstkankerscreening oudere vrouwen
borstkankersterfte
borstparende chirurgie
borstreconstructie
borstreconstructie na mastectomie
borstsparende chirurgie
borsttomosynthese
borstvoeding
bortezomib
bortezomib plus chemotherapy
bortezomib plus rituximab maintenance
BOSS cohort
BOSTON study
bot-SPNs
boteffect
botmetastasen
botmetastasen van mammacarcinoom
botmetastasering
botmicrometastasen
botox
botpijn
botsarcoom
bovenste-luchtwegkanker
BP-RMS
BPDCN
BPH
BPM
BPs
BR
BRAC1 2-mutation
brachytherapie
brachytherapy for glioblastoma
BRAF
BRAF 594 en 596 mutaties
BRAF 600 wild type melanoom
BRAF HER2 MET RET-alterations
BRAF mutation
BRAF non-V600-mutant mCRC
BRAF plus MEK inhibition
BRAF plus MEK inhibitors
BRAF V600-mutated mNSCLC
BRAF V600-mutated NSCLC
BRAF V600E
BRAF V600E mCRC
BRAF V600E mutated CRC
BRAF V600E-mutated biliary tract cancer
BRAF V600E-mutated CRC
BRAF wild-type advanced melanoma
BRAF-genfusies
BRAF-mutant mCRC
BRAF-mutant melanoma
BRAF-mutant mNSCLC
BRAF-mutated malignancies
BRAF-mutated melanoma
BRAF-remmer
BRAF-remmers
BRAF-remming
BRAF-V600 or BRAF-nonV600 mutated NSCLC
BRAF-V600E
BRAF-V600E mutated tumors
BRAF-wt advanced melanoma
brain cancer
brain imaging
brain metastases
brain metastases from melanoma
brain metastases in older patients
brain metastases nivolumab plus ipilimumab
brain metastases or leptomeningeal disease
brain metastasis
brain tumors
brain volume
brain-metastatic lung cancer
BRCA
BRCA mutation carriers with breast cancer
BRCA mutational status
BRCA-defective tumors
BRCA-mutatie
BRCA-related cancer
BRCA1
BRCA1 2 germline mutations
BRCA1 2 mtuation. risk of contralateral disease
BRCA1 2 mutation
BRCA1 2 mutation carriers
BRCA1 2 mutations
BRCA1 2 variants
BRCA1 2-mutatie
BRCA1 2-mutaties
BRCA1 2-mutations
BRCA1 2-negative Chinese breast cancer patients
BRCA1 and BRCA2 mutations
BRCA1 mutation
BRCA1-mutatie
BRCA2
BRCA2-associated breast cancer
BRCA2-mutaties
breast and lung cancer mortality in women
breast and prostate cancer
breast angiosarcoma
breast cancer
breast cancer –related lymphedema
breast cancer and other cancers
breast cancer bone metastasis
breast cancer brain metastases
breast cancer brain metastasis
breast cancer chemotherapy
breast cancer diagnosis
breast cancer family history
breast cancer in childhood cancer survivors
breast cancer in high-risk women
breast cancer in men
breast cancer in young women
breast cancer incidence before age 40
Breast Cancer Index
breast cancer leptomeningeal disease
breast cancer metastases
breast cancer metastatic recurrence
breast cancer molecular subtypes
breast cancer mortality
breast cancer mortality by comorbidty and age
breast cancer mortality rates in U.S. women
breast cancer outcomes
breast cancer ovarium cancer predisposition genes
breast cancer patients
breast cancer preventive effects of anastrozole
breast cancer recurrence
breast cancer risk
breast cancer risk after age 60
breast cancer risk in women ≥50 years
breast cancer screening
breast cancer screening among women with dense breasts
breast cancer screening in average-risk women
breast cancer subtype
breast cancer subtype incidence
breast cancer subtypes
breast cancer surgery
breast cancer survival
breast cancer survivors
breast cancer survivorship
breast cancer treated in neoadjuvant setting
breast cancer-related fatigue
breast cancer-related lymphedema
breast cancer-specific mortality
breast cancer-specific survival
breast compression
breast conservation
breast desmoid tumor management in France
breast ductal carcinoma in situ
breast intraepithelial neoplasia recurrence
breast milk paclitaxel excretion
breast MRI versus digital tomosynthesis
breast non-invasive disease
breast symptoms
breast-conserving surgery
breast-conserving therapy
breast-conserving therapy in women over 70
breastfeeding
brentuximab vedotin
brentuximab verdotin
brigatinib
BrighTNess study
BRIM-3 studie
BRIM7 study
BRIM8-studie
British Childhood Cancer Survivor Study
Broad-based genomic sequencing
BROCADE3 trial
BRPC
BRRM
bruton's tyrosine kinase
BTC
BTCRC-GU14-003 study
BTK
BTK inhibition
BTK inhibitor therapy
Burkitt lymphoma
Burkitt's lymfoom
busulfan plus fludarabine
busulfan plus melphalan conditioning
BV
BV plus AVD
BVD-523
C SCANS studie
C-486
C-ALCL
C-ETACs as hallmarks of cancer
C-ion RT
C-reactive protein
C-TASK FORCE studie
CA-125
CA180-226 studie
CA19-9
CA209-003 studie
CA209-003 trial
CA301 study
CABARET-studie
cabazitaxel
cabazitaxel plus carboplatin
cabazitaxel versus abiraterone or enzalutamide
CABONE study
CABOSUN
cabozantanib
cabozantinib
cabozantinib plus ADT
cabozantinib plus nivolumab with or without ipilimumab
cabozantinib versus everolimus
cachexia
CAD
CADC
CADM1 MAL-methylering
cadmium and lead in erythrocytes
cafeïne
caffeïne
CAG-repeat
CAIRO3
calcitonin receptor-like
calcium
calcium and magnesium intake
calcium supplementation
calciuminname
calculated tumor area
CALGB 40601 follow-up
CALGB 40903 study
CALGB 50604
CALGB 89803-studie
CALGB Alliance 140503
CALGB SWOG 80405 study
CALOR-studie
caloric restriction
CAM
CameL study
camrelizumab
camrelizumab plus apatinib
camrelizumab plus apatinib for advanced cervical cancer
camrelizumab plus gemcitabine plus oxaliplatin
camrelizumab plus GVD chemotherapy
cancer
cancer burden in patients with sleep apnea
cancer clinical trial participants
cancer deaths due to delays in diagnosis in England
cancer detection rate
cancer diagnosis
cancer diagnosis during adolescence
cancer diagnosis in primary care
cancer driver genes
cancer drugs approved based on response rate
cancer history
cancer immunotherapy trials
cancer in older adults
cancer in solid organ transplantation recipients
cancer incidence
cancer incidence and mortality
cancer incidence and spectrum in children
cancer incidence and survival in older adults
cancer mortality
cancer mortality in Europe
Cancer of unknown rimary
cancer outcomes
cancer patients
cancer patients and matched norm population perceived care and well-being
cancer patients treated with anticoagulation
cancer prevention
cancer recurrence
cancer risk
cancer risk after hematuria diagnosis
cancer risk in children
cancer risk in children and adolescents
cancer risk in individuals with major birth defects
cancer risk in women
cancer risks
cancer screening
cancer screening in people with mental illness
cancer spectrum
cancer surgical procedures
cancer survivors
cancer susceptibility genes
cancer-associated venous thromboembolism
cancer-related cognitive impairment
cancer-related fatigue
cancer-specific mortality
cancer-testis antigens
cancers with MUC16-variants
CANDOR study
canine lung cancer detection
cannabigerol
cannabis
CanSNET-studie
CANTO prospective cohort study
CANTO trial
CAO ARO AIO-04 study
CAO ARO AIO-04 trial post hoc analysis
CAP-studie
capecitabine
capecitabine versus observation
capivaserib for AKT1 E17K-mutated tumors
capivasertib
capivasertib for tumors with AKT mutations
capmatinib
CAPP-Seq
CAPP2 study
CAPRI-GOIM
CAPRICE
CAR T cell therapy
CAR T-cell therapy
CAR T-cellen voor solide tumoren
CAR T-celtherapie
CAR-T celtherapie
CAR-T-cell therapy in patients with advanced B-cell cancers and HBV-infection
CAR-transduced natural killer cells
CAR19 22 T-cell therapy
Caravaggio study
carbazitaxel
carbon ion RT
carboplatin dose capping
carboplatin plus pemetrexed
carboplatin with radiotherapy
carboplatin-etoposide with or without atezolizumab
carboplatin-paclitaxel with or without trastuzumab
carboplatine
carcinoïd tumoren
CARD study
cardiac events
cardiac impact of cytokine release syndrome
cardiac outcomes
cardiac safety
cardiale disfunctie
cardiale toxiciteit
cardiale veiligheid
cardiometabolic risk factors and survival after cancer
cardiopulmonary complications
cardiorespiratorische fitheid
cardiorespiratory fitness
cardiotoxiciteit
cardiotoxiciteit anthracylines
cardiotoxiciteit chemotherapie
cardiotoxicity
cardiovasculair risico
cardiovasculaire toxiciteit
cardiovascular adverse events
cardiovascular disease
cardiovascular disease risk
cardiovascular diseasse
cardiovascular events
cardiovascular outocmes
cardiovascular risk
cardiovascular toxicity
carfilzomib
carfilzomib for myeloma
CARMENA study
CARMENA-studie
carmustine
Carolina Breast Cancer Study
carotenoïden
carpaal-tunnelsyndroom
CARRIERS consortium
CARTS study
cascade genetic testing
CASPIAN study
CASPIAN study follow-up
CASPS study
CASR
CASSINI study
CASSIOPEIA study
CASTOR and POLLUX age subgroup analysis
CASTOR subgroup analysis
castratieresistent prostaatcarcinoom
castration-resistant prostate cancer
CATCH
catch-up HPV-vaccination
CATNON-studie
catumaxomab
cause of death
cause-specific mortality
cause-specific mortality after initial chemotherapy
causes of death
causes of death after breast cancer diagnosis
CBC
CBC prediction
CBC risk
CBC-risico
CBCSG010 study
CBTRUS
CBTS
cc mRCC
CC-223
CC-486
CCEC
CCNE1 expression
CCR7
ccRCC
ccRCC brain metastases
CCRT
CCSS
CD103+ immune cells
CD19 CAR-T cell therapy
CD19 CAR-T cell therapy in children and young adults
CD19-positive lymphoid tumors
CD22-directed CAR T-cell therapy
CD4
CD4+ percentage
CD45-targeted antibody-radionuclide conjugate
CD47 blockade plus rituximab
CD8+ T cell infiltration
CDG
CDH1 mutation carriers
CDK12-mutated prostate cancer
CDK4 6 inhibition
CDK4 6 inhibitor plus AI
CDK4 6 inhibitors
CDK4 6-remming
CDKN2A homozygous deletion
CDKN2C
CDS
CDX-110
CDX2
CEA
CEA-specifieke T-cel respons
cediranib
CEGT
celecoxib
CELESTIAL trial
cell nest size
cell-free circulating tumor DNA variant allele frequency
cell-free DNA multicancer early detection test
cell-free Epstein-Barr virus DNA
cell-free urine
cellulaire immuuntherapie
cellular immune activation
CelTIL-score
celvrij circulerend tumor DNA
cemiplimab
central adiposity
central adiposity and risk of subsequent breast cancer by menopause status
centrale adipositas
cerebellopontine angle tumors
cerebrospinal fluid microRNA signatures
cerebrospinal fluid tumor DNA genotyping
cerebrospinale vloeistof
ceritinib
cervical cancer
cervical cancer and precancer risk
cervical cancer incidence
cervical cancer screening
cervical cancer survivors
cervical dysplasia after HPV vaccination
cervical HPV-testing
cervical neoplasia
cervical screening
cervicale glandulaire neoplasie
cervicale intra-epitheliale neoplasie graad 3
cervicale intraepitheliale neoplasie
cervicale-slokdarmkanker
cervixcarcinoom
cervixcarcinoomscreening
cervixconisatie
cervixkanker
cervixkankerscreening
cervixlaesies
CESM
CeTeG NOA-09 study
CETSA
cetuximab
cetuximab-IRDye800
cetuximab-related infusion reactions
cetuximab-resistant recurrent metastatic HNSCC
cetuximab-resistentie
CEVOREM trial
CF-WBI
cfDNA
cfDNA genotyping
cfDNA methylation signatures
CGC
cGVHD
ch
CHAARTED-analyse
CHAARTED-studie
change in PD-L1 expression
change in serum uric acid level
change of breast cancer subtype during neoadjuvant chemotherapy
changes in length and complexity of oncology guidelines since 1996
changes in taste and smell of food
characteristics and outcomes
characteristics in young versus old patients
Charlson-score
ChcekMate 066 five-year results
CHD
CheckMate 012
CheckMate 016-studie
CheckMate 017 and 057 trials
CheckMate 017 en 057
CheckMate 017 en CheckMate 057
CheckMate 017-studie
CheckMate 025
CheckMate 026-studie
CheckMate 032 study
CheckMate 037
CheckMate 040
CheckMate 040 study
CheckMate 064
CheckMate 066
CheckMate 066 study
CheckMate 067
CheckMate 067 five-year survival
CheckMate 069
CheckMate 069 066 en 067
CheckMate 141
CheckMate 141-studie
CheckMate 142
CheckMate 143 study
CheckMate 153
CheckMate 204 study
CheckMate 205 study
CheckMate 214
CheckMate 214 long-term follow-up
CheckMate 214 study
CheckMate 227 part 1 three-year update
CheckMate 227 study
CheckMate 227-studie
CheckMate 238 four-year results
CheckMate 238-studie
CheckMate 275
CheckMate 358 trial
CheckMate 370-studie
CheckMate 384 study
CheckMate 436 study
CheckMate 511 trial
CheckMate 568
CheckMate 743 trial
CheckMate 817
CheckMate 9ER trial
CheckMate 9LA study
CheckMate-032 study
CheckMate-142
checkpoint blockade
checkpoint blockade immunotherapy
checkpoint inhibitor therapy
checkpoint inhibitors for various types of melanoma
checkpoint kinases
CHEK2 1100delC
CHEK2 germline pathogenic variants
CHEK2-mutaties
CHEK2*1100delC
chemerin plasma concentration
chemobrain
chemoimmunotherapy
chemopreventie mammacarcinoom
chemopreventie van mammacarcinoom
chemoprevention of CRC
chemoprevention with low-dose aspirin
chemoradiotherapie
chemoradiotherapy
chemoradiotherapy versus radiotherapy
chemoradiotherapy with proton versus photon therapy
chemorefractory metastatic colorectal cancer
Chemoresistentie
chemosensitizatie
chemotherapie
chemotherapie tijdens zwangerschap
chemotherapie-geïnduceerd ovariumfalen
chemotherapie-geïnduceerd POF
chemotherapie-geïnduceerde febriele neutropenie
chemotherapie-geïnduceerde misselijkheid en braken
chemotherapy
chemotherapy adherence
chemotherapy after colorectal cancer liver metastasectomy
chemotherapy alone versus combined modality therapy
chemotherapy and ICU admission in last phase of life
chemotherapy benefit
chemotherapy demands
chemotherapy for breast and prostate cancer
chemotherapy for childhood cancer
chemotherapy for early-stage breast cancer in older women
chemotherapy free treatment
chemotherapy plus atezolizumab for NSCLC
chemotherapy plus immunotherapy
chemotherapy plus ponatinib
chemotherapy regimens
chemotherapy response
chemotherapy response score
chemotherapy versus observation
chemotherapy with bevacizumab or temsirolimus
chemotherapy with or without cetuximab
chemotherapy with or without pembrolizumab
chemotherapy with versus without bevacizumab
chemotherapy-free treatment
chemotherapy-induced alopecia
chemotherapy-induced amenorrhea
chemotherapy-induced cardiotoxicity
chemotherapy-induced nausea and vomiting
chemotherapy-induced neutropenia in adult NSCLC-patients
chemotherapy-induced peripheral neuropathy
chemotherapy-induced thrombocytopenia
chemotherapy-ineligible HL patients
chemotherapy-naïve non-squamous NSCLC
chemotherapy-related cognitive impairment
chemotherapy-related hematological toxicity
chemotherapy-related vomiting in children and adolescents
chest-irradiated cancer survivors
CHF
CHHiP-studie
child self-report versus caregiver report
childbearing potential
childbirth
childhood ALL
childhood ALL survivors
childhood AML
childhood and adolescent ALL in The Netherlands 1990-2015
childhood and AYA cancer survivors
childhood B-ALL
childhood brain tumors
childhood cancer
childhood cancer survival in immigrants
Childhood Cancer Survivor Study
childhood cancer survivors
childhood leukemia
childhood leukemia and lymphoma survivors
childhood leukemia risk
childhood leukemia; maternal hormonal contraception use
childhood nasopharyngeal carcinoma
children
children and adolescents with cancer
children and AYAs with cancer
children with cancer
Children’s Oncology Group
Children’s Oncology Group AALL0434 study
Children’s Oncology Group study
Children’s Oncology Group Study AALL03N1
chimeric antigen receptor
Chinese Alliance for Research in Thymomas database
CHIP
chirurgie
cHL
cHL in young patients
choice between first-line endocrine versus chemotherapy
cholangiocarcinoma
cholangiocarcinoom
cholecystitis
chondrosarcoma
chondrosarcoom
CHOP
CHOP with or without alemtuzumab
chordoma
chordoom
chromische lymfocytische leukemie
chromocolonoscopy versus white-light colonoscopy
chromosoom 21
chromosoominstabiliteit
chromothripisis
chronic comorbidities
chronic health conditions
chronic lymphocytic leukemia
chronic myeloid leukemia
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
chronic pain
chronic phase CML
chronical medical conditions and late effects in survivors
chronisch graft-versus-host disease
chronische fase CML
Chronische fase-CML
chronische lymfatische leukemie
chronische lymfocytische leukemie
chronische lymfoide leukemie
chronische myelomonocytische leukemie
Chronos-1
CHRONOS-1 study two-year follow-up
chubb
chyleuze ascites
CIA
cigarette type
cilengitide
CIMBA
CIMP
CIN
CIN 3
CIN2 3
CIN2+ detection
CINP
CINV
CIO
CIOD
CIPN
circadiaan ritme
circulating breast cancer risk factors in normal weight postmenopausal women
circulating DNA
circulating HPV DNA
circulating immune cells
circulating levels of specific lipid groups
circulating sex hormone levels
circulating tumor cells
circulating tumor DNA
circulerend DNA
circulerend tumor-DNA
circulerende tumorcellen
circulerende tumorcellen; detectie nieuwe mutaties
circulerende vetzuren
CIRT
CIRT for unresectable pelvic bone sarcoma
CISIG
cisplatin
cisplatin and fluorouracil versus carboplatin and paclitaxel
cisplatin for cancer in children
cisplatin-induced hearing loss in children and AYAs
cisplatin-ineligible operable high-risk UC
cisplatine
CITN-10 study
citrusfruit
cixutumumab
CLAP study
ClarIDHy study
CLARITY study
CLASS02 trial
claudine 18.2
CLEAR
clear cell renal cell carcinoma
CLEAR trial
CLEOPATRA study final results
Clevers
clinical and genomic risk
clinical calculator for prediction of recurrence
clinical characteristics
clinical characteristics and outcomes
clinical features
clinical features for prediction of survival
clinical meaningful outcomes
clinical outcomes
clinical outcomes and prognostic factors
clinical prognostic stage group system
clinical stage I gastric cancer
clinical stage I nonseminoma
Clinical Treatment Score at 5 years
clinical trial enrollment
clinical trial evidence
clinical trial participation
clinical trials
clinical utility of qPCR plasma EGFR mutation detection in advanced lung cancer
clinically N2 non-small cell lung cancer
clinicogenomic classifier
CLL
CLL 2007 SA-studie
CLL in patients intolerant to BTK inhibitor or PI3K inhibitor
CLL in younger patients
CLL resistant to venetoclax
CLL SLL
CLL therapies after venetoclax discontinuation
CLL with coexisting conditions
CLL-IPI
CLL10
CLL2-BAG study
CLLM1-studie
CLM
CLND
clofarabine
clofarabine plus total body irradiation conditioning
CLOG1302-studie
clomid
clomifeen
clomifeencitraat
Clozel
CLUE II cohort
CME
CML
CML after ABL kinase inhibitor failure
CML in chronic phase
CML-BP
CML-CP
CML-studie IV
CMM
CMML
CMS risk
CMSs
CMV
CMV viremia after hematopoietic stem cell transplant
CMV-viremie
CN-AML
CNAs
CNBSS
CNS efficacy
CNS lymphoma
CNS metastases
CNS metastases of breast ancer
CNS metastasis
CNS NGGCTs
CNS response
CNS tumors in children
CNS-DLBCL
CNS-lymfoom
CNS-metastasen
CNS-recidief HER2-tumoren
CNS-tumoren
CNS-tumoren; impact van behandelcentrum
co-occuring NOTCH and HR mutations
CO.26 study
cobas
cobimetinib
cobimetinib plus vemurafenib
COBRA study
COBRA-score
coBRIM-studie
cochlear radiation dose
coffee intake
COG AALL0434
COG AALL0622-studie
COG AALL0932 study
COG AALL1331 study
COG AAML0631-studie
COG ARAR0331 study
COG AREN0533-studie
COG trial ACNS0333
COG-studie AAML0531
COG-studie AREN0532
cognitief functioneren
cognitieve disfunctie
cognitieve klachten
cognitieve veranderingen na chemotherapie
cognition
cognition after endocrine versus chemoendocrine therapy
cognitive and neurobehavioral impairment
cognitive performance
cohabitation and breast cancer risk
COIN colorectal trial
colectomie
collider stratification bias
COLOFOL-studie
Cologuard
colon cancer
colon cancer drug metabolism
Colon Cancer Family Registry
colon cancer peritoneal recurrence
colon cancer risk
colon cancer surgery
colon surgery
colon-NET
coloncarcinogenese
coloncarcinoom
colonkanker
colonoscopie
colonoscopy-based CRC screening
colorectaakanker
colorectaaladenomen
colorectaaladenoom
colorectaalcarcinoom
colorectaalkanker
colorectaalkankerscreening
colorectaalneoplasie
colorectaalpoliepen
colorectal
colorectal adenomas
colorectal cancer
colorectal cancer incidence in Americans approaching screening age
colorectal cancer lever metastasis
colorectal cancer molecular subtypes
colorectal cancer mortality
colorectal cancer precursors
colorectal cancer risk
colorectal cancer screening
colorectal carcinogenesis
colorectal liver metastases
colorectale chirurgie
colorectale levermetastasen
colorectale neoplasie
coloscopie
COLUMBA study
COLUMBUS trial
COMBI-AD studie
COMBI-AD study
COMBI-d studie
COMBI-MB studie
COMBI-v
CombiDT
combination of HAI and systemic chemotherapy
combination of HDAC and mTOR inhibition
combination of osimertinib and bevacizumab
combined analysis of N9831 and NSABP B-31
combined BRAF- and MEK-inhibition plus PD-1 blockade
combined CTLA-4 and PD-1 inhibition
combined effect of breast density and BMI
combined lifestyle factors
combined modality treatment
combined nivolumab and bevacizumab
combined PD-1 blockade and VEGF inhibition
combined-modality therapy
commercial gene expression tests
common cancers
common medications
CoMMpass study
community jury
comorbiditeiten
comorbidities
comparative safety of ICIs
comparison between men and women
comparison Hong Kong and USA
comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing HSCT
comparison of clinical studies and real-world outcomes
comparison of first-line treatments
comparison of five guidlelines
comparison of systemic treatments
comparison of two RT fractionation schedules
COMPASS study
complementaire en alternatieve behandelingen
complementary and alternative medications
complementary medicine
complete mesocolic excision
complete remission with vismodegib
complete response to neoadjuvant CRT
COMPLETE study
complex karyotype
complication rate and outcomes
complication risk
COMPOSE-studies
composite GRFS and CRFS outcomes
compromised immune microenvironment
computationele pathologie
computer-assisted colorectal adenoma detection
Computer-geassisteerde chirurgie
conclusions of publcations
concomitant mutations
concomitant use
CONCORD-2
CONCORD-3
concurrent chemoradiotherapy
conditional immune toxicity rate
conditional recurrence-free survival
conditional survival
conditional survival after five recurrence-free years
conditional survival after resection
conditionele ziektevrije overleving
CONDOR trial
congenital heart disease
congestive heart failure
conjunctival melanoma
CONKO-004
connexine 30
consensus molecular subtypes
conservative management
CONSIGN
consistent physical activity
consolidation radiotherapy
consolidation with WBRT or stem-cell transplantation
consoliderende radiotherapie
Consomic Xenograft Model
contemporary hormonal contraception
contemporary lenalidomide-based regimens
contemporary radiation therapy for ESFHL
continuation of screening after age 70 years
continuous tumor-size-based end points
continuous versus 1-year nivolumab
continuous versus intermittent dosing of dabrafenb-trametinib
CONTINUUM-studie
contralateraal mammacarcinoom
contralateral breast cancer
contralaterale borstkanker
contralaterale mastectomie
contralaterale profylactische mastectomie
conventional versus moderate hypofractionated RT
conversion surgery
CONVERT-studie
CONVINCE-studie
copanlisib
copanlisib plus gemcitabine
COPD
COPD and lung cancer
copy number alteration screening
copy number loss
corpus uteri cancer
correlation of CTCs or DTCs with Oncotype DX recurrence score
corticosteroïden
corticosteroids
COSMOS trial
cost-effective global care for cancer in children
cost-effectiveness
cost-effectiveness of CAR T-cell therapy
cost-effectiveness of intraoperative MRI
cost-effectiveness of lung cancer screening
cost-effectiveness of prostate RT
cost-effectiveness of surveillance
Costa RIca
Costa Rica HPV Vaccine Trial
cotinine
COVID-19
COVID-19 first wave
COVID-19 hospitalized patients
Covid-19 hospitalized patients with lymphoma
COVID-19 in patients with hematological malignancies
COVID-19 in patients with thoracic malignancies
COVID-19 mortality in patients with various cancers
COVID-19 pandemic
COVID-19 severity and outcomes in patients with cancer
COVID-19-infected cancer patients
COVIDSurg Collaborative
coxibs
CP-CML
CP-genen
CPA use
CpG-B
CPI-613
CPIs
CPM
CPPT
CPX-351
CRA
craniopharyngioma in adults
craniotomie
CRBSI
crc
CRC detection
CRC diagnosis
CRC in Taiwan
CRC incidence
CRC incidence and mortality after polypectomy
CRC incidence and mortality after snigle negative screening colonoscopy
CRC incidence in Canada
CRC intrinsic subtypes
CRC liver metastases
CRC prognosis
CRC risk
CRC risk in Lynch syndrome
CRC stage distribution
CRC survival
CRC survivors
CRC with asymptomatic synchronous metastases
CRC with ERBB2 amplification overexpression
CRC with high tumor mutaional burden
CRC-biomarkers
CRC-diagnose
CRC-risico
CRC-screening
CRCD
CREATE-studie
crenigacestat
CRF
cribriform groeipatroon
CRICKET trial
crizotinb
crizotinib
crizotinib-resistant ALK-positive NSCLC
CRLM
CRLX101
CRN
Crohn’s disease
CROSS
CROWN study
CROWN Trial
CRP
CRP flare-response
CRP-niveau
CRPC
CRPC with bone metastases
CRS
CRS HIPEC
CRS-207
CRS-HIPEC cost effectiveness
CRT
CRT for esophageal cancer
CRT versus CT
CRT with cisplatin versus cetuximab
cryoablation for lung metastases
CSCC
CSCCs
CSF penetration of anti-PD-1 antibodies
CSM
CT
CT examinations
CT lung cancer screening
CT-based biomarkers
CT-longkankerscreening
CT-P10
CT-screening longkanker
cT1-2N0 breast cancer
cT1T2No OTSCC
CTCAE
CTCL
CTCs
CTCs and early relapse
ctDNA
ctDNA after neoadjuvant chemotherapy
ctDNA alterations
ctDNA analysis
ctDNA analysis to direct therapy
ctDNA and risk of progression after long-term response
ctDNA as response indicator
ctDNA markers for early progression
ctDNA mutations
ctDNA predicts response and prognosis
ctDNA reflects response and survival
ctHPVDNA monitoring in recurrence surveillance
CTL019 for pediatric B-ALL
CTLA-4
CTLA-4 blokkade
CTLC
CTONG1104 study
CTP
CTS5 risk score
CUDC-907
CUETO
cumulative GRAS score
CUP
curatie
curative-intent resection
current or former smoking
cutaan squameus celcarcinoom
cutaan squameus celcarcinoom van hoofd en hals
cutaan T-cel lymfoom
cutane bijwerkingen
cutaneous adverse events
cutaneous BCC
cutaneous HNSCC with regional lymph node metastasis
cutaneous malignant melanoma
cutaneous melanoma
cutaneous squamous cell carcinoma
cutaneous toxicities
CUX1-ALK rearrangement
CVD
CVD risk after GnRH agonists versus GnRH antagonists
CVSS-studie
CXB
CXCL8-CXCR1 2 axis
CXM
cycline D1
cyclofosfamide
cyclophosphamide
cyclophosphamide-bortezomib-dexamethasone
CYP2D6 genotype
CYP3A
cyproteronacetaat
cyramza
cystectomie
cytarabine
CYTO-CHIP study
cytogenetically defined high-risk multiple myeloma
cytogenetisch normaal AML
cytokine-induced killer cell therapy
cytokines
cytology testing
cytoreductive surgery
Cytosponge-trefoil factor 3
D-2-hydroxyglutaraat
D-index-guided early antifugal therapy
D-Rd
D-Rd versus Rd
D-VCd
D-Vd versus Vd
D-VMP
D-VTd versus VTd for newly diagnosed multiple myeloma
DA-EPOCH-R versus R-CHOP
dabrafenib
dabrafenib plus trametinib
dabrefenib plus trametinib
dacomitinib
DADI
DAFI
daily aspirin
dairy intake during adolescence and risk of colorectal adenoma
DALLT cohort
daratumumab
darm-microbioom
darm-stamcellen
darmflora
darmkanker
darolutamide
DARPin drug candidate MP0250
DART S1609 neuroendocrine cohort
DART SWOG 1609
DART-studie
dasatinib
dasatinib plus blinatumomab
dasatinib versus imatinib
DASCERN randomized study
DATA-studie
David A. Karnofsky Memorial Award and Lecture
davoli
DAWN-studie
DAWT
DBCG 07-READ studie
DBCG HYPO trial
DBMS
DC-CIK
DCd with or without P
DCE-MRI
DCF chemotherapy
DCIS
DCIS and early stage HR-positive breast cancer
DCIS and node-negative breast cancer
DCIS before age 50 years
DCIS grading
DCOG-LATER cohort
DCOG-LATER cohort study
DCOG-LATER studie
dd-chemotherapie
DDCT
DDR gene aberrations
DDR gene mutations
de novo metastatic nasopharyngeal carcinoma
de novo metastatic prostate cancer
de novo stage IV HER2-positive MBC
De-ESCALaTE HPV study
de-escalation of axillary surgery
de-escalation of TKIs
death from unintentional injury among cancer patients
Debio 1143 plus high-dose cisplatin CRT
Debio0932
Decipher
decision support system
decitabine
dedifferentiated chordoma
deep learning
deep learning model
deep molecular response
deepening of response after completing therapy
defactinib
deficient mismatch repair stage III colon cancer
definitive radiotherapy
definitive stereotactic body radiotherapy
degarelix
DEL
delay of cancer surgery
delayed hearing loss
delirium
dementia
Denemarken
denosumab
dense breast tissue
dentaal trauma
depatux-M
depressie
depression
depression and suicidal ideation
depth of response
dermatofibrosarcoma protuberans
desmoïd
desmoid tumors
DESMOPAZ study
DESTINY study
DESTINY-Breast01 study
DESTINY-Gastric01 study
DESTINY-studie
detectie
Detectie borstkanker
detectie colorectaalkanker
detecting genomic biomarkers in plasma versus tissue
detection advanced neoplasia
detection bias
detection early-stage OPSCC
detection of circulating tumor DNA after surgery for nmCRC
detection of CTCs during follow-up
detection of invasion of detrusor muscle
detection of microsatellite instability
detection of mutations in ctDNA
detection of non-index lesions
detection of prostate cancer
detection of relapse
determinants of breast cancer risk
determinants of optimal adjuvant therapy
determinants of outcomes
determinants of survival
determinants of tumor cell PD-L1 expression
dexamethason
dexanethasone
dexrazoxane
DFP-10917
DFS
DHA
DHAP
DHL
DHL and THL
diabetes
diabetes and cancer risk
diabetes mellitus
diagnose longcarcinoom
diagnosis and treatment
diagnostic low-dose ionizing radiation in youth
diagnsotic performance of feacal immunochemical test
DICER1 pathogenic variants
diet qualiity
diet quality
dietary carbohydrate quality and human health
dietary fiber
dietary fiber and yogurt
dietary intake
dietary intake of antioxidants
dietary modification and breast cancer mortality
dietary polyunsaturated fat
dietary supplement use
dietary supplement use during chemotherapy
differences in treatment outcomes
different cancer types
differential ribosome measurements of codon reading
differentiated thyroid cancer
difficult patients
diffuse large B cell lymphoma
diffuse large B-cell lymphoma
diffuse large B-cell lymphoma-specific mortality
Diffuse optical spectroscopic imaging
diffuse type TGCT
diffuse-type giant cell tumor
diffusion-weighted MRI
diffuus grootcellig B-cel lymfoom
diffuus intrinsiek ponsglioom
difluoromethylornithine maintenance
digestive tract cancer
digital breast tomosynthesis
digital breast tomosythesis
digital screening mammografie
DigniCap
digoxine
DII
DIPG
DIPG-BATS studie
direct-acting antivirals
discontinuation imatinib for CML in children
discontinuation of anti-PD-1 antibody therapy
discontinuation of first-line dasatinib for CML
discontinuation of immune suppression
discontinuation of TKIs for de novo CP-CML
disease progression in cancer patients
disease trajectories and mortality after breast cancer
disease-free survival
diseases and deaths in middle-aged adults
disontinuation of trastuzumab
disparities by race ethnicity and age
disruption of FIT-screening programmes
distal cholangiocarcinoma
distal rectal cancer
distale pancreatectomie
distant disease-specific survival
distant metastasis of salivary gland cancer
distant metastatic breast cancer
distant recurrence of breast cancer
distress
Distress Thermometer
DLBCL
DLBCL survivors
DMFS
dMMR CC
dMMR PDAC
DN
DNA damage immune response
DNA Damage Immune Response signatrue
DNA promoter-hypermethylering
DNA repair gene aberrations. platinum-base chemotherapy
DNA-methylering
DNA-test
DNMT3A-mutatie
docetaxel
docetaxel-cyclophosphamide for breast cancer
documentaire
doelgerichte behandeling
donor clonal hematopoiesis
DoR
DOREMY study
dormancy-genen
dose dense doxorubicin-cyclophosphamide and-paclitaxel
dose optimization
dose reduction of preoperative RT
dose-adjusted EPOCH-R
dose-dense adjuvant chemotherapy plus trastuzumab
dose-dense versus standard chemotherapy
dosisescalatie
DOSISPHERE-01 study
dostarlimab
DOT1L
double expressor DLBCL
DOVIGIST-studie
doxorubicin delivery from ultrasound-triggered liposomes
doxorubicin plus pembrolizumab
doxorubicine
DPP-4 inhibition for aGVHD proylaxis
DPYD genotyping
DPYD*2A variant carrying cancer patients
DREAM study
DREAMM-2 study
droge mond
droplet digital PCR
drug response predictor
drug-drug interactions
drye eye syndrome
DSMM XI-studie
DSRCT
DSTP30865
dt-GCT
DTC
DTCs
DTX3 copy number in breast cancer
ductaal carcinoom in situ
ductal carcinoma in situ
DUD
dunne-darmadenocarcinoom
dunne-darmneoplasie
DUO Crossover Extension Study
DUO study
duration of adjuvant trastuzumab
duration of response
durvalumab
durvalumab for solid tumors in HIV-1 infected patients
durvalumab or placebo after CRT for stage III NSCLC
durvalumab plus chemotherapy
durvalumab plus olaparib plus cediranib
durvalumab with or without tremelimumab
durvalumab-cisplatin-pemetrexed
DURVAST study
dutasteride
Dutch Bone Metastasis Study
Dutch MINDACT cohort analyis
duvelisib
DYNAMIC study
DYNAMO study
DYPD genotyping
dysfagie
dyslipidemia
dyspnoe
e-sigaretten
E1609 study
E1912 study
E2F8
E3805-studie
E3A06 study
E3N
E3N cohort
E4
E5103 study
E75
EA
EAC
EADC
EAGLE study
early and locally advanced breast cancer
early AYAs
early breast cancer
early breast cancer or ductal carcinoma in situ
early cancer surveillance
early detection and monitoring progression of gastric cancer
early diagnosis
early discontinuation of endocrine therapy
early donor identification
early experience
early HER2-positive breast cancer
early interdisicplinary supportive care
early melanoma recurrence despite adjuvant anti-PD-1 therapy
early metabolic response
early mortality
early noninvasive detection of response
early onset CRC
early onset female cancer survivors
early palliative care use
early phase ICI-trials
early predictors of pathologic complete response to neoadjuvant therapy
early recurrence
early stage breast cancer
early stage breast cancer in older women
early stage breast cancer outcome
early stage ER-positive breast cancer
early stage prostate cancer
early stage TNBC
early thymic precursor acuut lymfoblastische leukemie
early thymic precursor-like phenotype ALL
early TNBC
early trastuzumab interruption
early triple-negative breast cancer
early-life alcohol intake
early-onset colorectal cancer
early-onset CRC
early-onset familial breast cancer
early-onset severe infections
early-stage breast cancer
early-stage breast cancer in elderly patients
early-stage breast cancer in the elderly
early-stage breast cancer recurrence
early-stage cancers
early-stage cervical cancer
early-stage endometrial cancer
early-stage Hodgkin lymphoma
early-stage HR-positive breast cancer
early-stage lung cancer
early-stage non-small cell lung cancer
early-stage non-small lung cancer
early-stage NSCLC
early-stage oropharyngeal squamous cell carcinoma
early-stage pediatric HL
early-stage unfavorable classic Hodgkin lymphoma
early-stage unfavorable HL
EBCC-12 postponed
EBRT for localized prostate cancer
EBV
EC
ECD
Echelon-1 studie
ECHELON-1 study
ECHELON-2 study
ECHO-202 KEYNOTE-037
ECOG PS
ECOG PS 2
ECOG-ACRIN 2511 study
ECOG-ACRIN 5508 study
ECOG-ACRIN E1412 study
ECOG-ACRIN E1912 study
ECOG-PS
economic evaluation
ECX)
Edinburgh Pain Assessment and management Tool
educational level
één-maands mortaliteit
eenarmige versus gerandomiseerde fase 2-studies
eerdere kanker
EF-14
effect modifiers of low-dose tamoxifen
effect on early cancer detection
effects of GVHD on long-term outcomes
efficacy of immunotherapy
efficacy of medications for reduction of risk of primary breast cancer in women
EFVPTC
EGFR
EGFR amplified glioblastoma
EGFR copy number gain
EGFR inhibition resistance
EGFR mutated advanced non-small cell lung cancer
EGFR mutated NSCLC
EGFR mutation-positive advanced NSCLC
EGFR mutation-positive MET-amplified NSCLC after EGFR TKIs
EGFR mutation-positive NSCLC with leptomeningeal metastases
EGFR T790M
EGFR T790M-positive advanced NSCLC with leptomeningeal metastases
EGFR T790M-positive NSCLC
EGFR T790M-positive NSCLC in elderly patients
EGFR therapy resistant NSCLC
EGFR-amplified recurrent glioblastoma
EGFR-blokkade
EGFR-mutant and MET-amplified NSCLC
EGFR-mutant lung adenocarcinoma
EGFR-mutant lung cancer
EGFR-mutant non-small cell lung cancer
EGFR-mutant NSCLC
EGFR-mutant NSCLC with liver metastases
EGFR-mutated advanced non-small cell lung cancer
EGFR-mutated advanced non-small-cell lung cancer
EGFR-mutated advanced NSCLC
EGFR-mutated lung adenocarcinoma
EGFR-mutated non-small cell lung cancer
EGFR-mutated NSCLC
EGFR-mutated NSCLC in elderly or frail patients
EGFR-mutatie
EGFR-mutaties
EGFR-TKI
EGFR-TKIs
EGFR-TKIs for stage IIIB IV EGFR-mutant NSCLC
EGFR+ and ALK+ NSCLC
EHCC
eierstokkanker
eiwitbiomarkers
elacestrant (RAD1901)
ELCC 2017
elderly cancer patients
elderly HR-positive breast cancer patients
elderly patients
electric power morcellation
electronic nose
electroporated plasmid IL-12
ELEVATE TN study
elevated vitamin B12 levels
ELIANA study QOL analysis
Eliasof
ELOQUENT-3 study
elotuzumab
ELRP
ELSA
eltrombopag
ELTS-score
emactuzumab
EMBRACA study
EMBRACA-studie
EMBRACE-studie
embryonale hersentumoren
EMD
emergency department use and unplanned hospitalization
EMERGING-CTONG 1103 study
emesis
emetogenic chemotherapy in pediatric patients
EMILIA
emotionele uitputting
EMPOWER-Lung 1 trial
EMT
EMVI
encorafenib
encorafenib plus binimetinib
ENCORE-601 study
end-of-life care
end-of-life zorg
ENDEAVOR-studie
ENDOANGEL system
endocriene behandeling
endocriene effecten
endocriene therapie
endocrine deficiency
endocrine diseases
endocrine therapies
endocrine therapy
endocrine therapy adherence
endocrine therapy for breast cancer
endocrine therapy resistance
endocrine treatment
endocrine treatment versus chemotherapy
endocrine-responsive lobular carcinoma of the breast
endometrial ancer
endometrial cancer
endometrial cancer risk
endometrial cancer surgery
endometrial cancer survival
endometrioïd endometriumcarcinoom
endometrioïd epitheliaal ovariumcarcinoom
endometrium-adenocarcinoom
endometriumcarcinoom
endometriumkanker
EndoPredict
endoscopic or open resection
endoscopic surgery versus intensity-modulated radiotherapy
endotheliaal ovariumcarcinoom
ENDS
ENDURANCE trial
energetic capacity
ENESTfreedom
enfortumab vedotin
ENGOT-OV16 NOVA study
ENGOT-OV16 NOVA trial
enhanced recovery after surgery
enhancer of zeste homolog 2
ENITEC consortium
ENKTL
ENLIVEN study
ENOC
enocrafnib
ensartinib
entecavir
enterovirus
enthusiasm hypothesis
entospletinib
entrectinib
Environmental Quality Index
enzalutamide
enzalutamide for castration-resistant prostate cancer
enzalutamide plus trastuzumab
enzalutamide versus bicalutamide
ENZAMET study
enzastaurine
EOC
EOPM
EORTC
EORTC 10995
EORTC 1325 Keynote-054 studie
EORTC 1325 KEYNOTE-054 study
EORTC 1325-MG KEYNOTE-054 3-year follow-up
EORTC 18071
EORTC 22922 10925 study
EORTC 22922 10925-studie
EORTC 22952-26001 trial exploratory analysis
EORTC 26101 analysis
EORTC study 22033-26033
EORTC-62092
EPA
epacadostat
EpCAM-positieve tumoren
ependymoom
epertinib
EPHOS-B
epi-drugs
EPIC
EPIC cohort
EPIC-analyse
EPIC-NL
EPICAP-studie
epichaperome-targeted positron emission tomography for tumor imaging
epidemiology and outcomes
epidural use
epidurale metastasen
epigenetic editing
epigenetische stabiliteit
epigenetische veranderingen
epilepsy risk factors
epirubicin
epitheliaal ovariumcarcinoom
epithelial ovarian cancer
epithelial ovarian cancer risk
epithelial ovarian cancer survivors
epithelial ovarian carcinoma
Epitopes-HPV02 ancillary study
Epitopes-HPV02 study
EPOC
EPOC1706 study. advanced gastric cancer
eprenetapopt (APR-246) plus azacitidine
eprenetapopt plus azacitidine
EPSILoN
Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte
EQoL-MDS
ER positive breast cancer
ER status
ER status and breast cancer survival
ER- en PR-testen
ER-negatief mammacarcinoom
ER-negatieve borstkanker
ER-negatieve tumoren
ER-positief HER2-negatief gevorderd mammacarcinoom
ER-positief mammacarcinoom
ER-positieve borstkanker
ER-positive advanced breast cancer
ER-positive advanced breast cancer after aromatase inhibitor failure
ER-positive breast cancer
ER-positive early-stage breast cancer
ER-positive HER2 negative breast cancer
ER-positive HER2-negative breast cancer
ER-positive HER2-negative MBC
ER-positive HER2-negative primary breast cancer
ER-positive node-positive breast cancer in elderly patients with comorbidities
ER+ HER2-
ER+ HER2- BC
ER+ HER2- breast cancer
ERA 223 study
eRAPID intervention
ERAS
ERBB2 HER2-positive metastatic breast cancer
ERBB2 mutations in solid tumors
ERBB2 plasma copy number
erdafitinib
Erdheim-Chester disease
erfelijke borst- en eierstokkanker
erfelijke syndromen
erfelijkheid
ERG- and PTEN-defined prostate cancer
eribulin
eribulin plus everolimus
eribulin with or without pembrolizumab
eribuline
ErkentNIS
erlotinib
ersatzdroge
Erβ1
Erβ2
ES-NSCLC
ES-SCLC
ES-SCLC after platinum-based chemotherapy
ESAS-scores
ESCC
ESCC detection by microRNA profiling
ESCORT study
ESD
ESGC
ESHAP
ESMO
esomeprazole
esophageal adenocarcinoma
esophageal and GEJ adenocarcinoma
esophageal cancer
esophageal squamous cell carcinom
esophageal squamous cell carcinoma
esophagogastric cancer surgery
ESPAC-4 secondary analysis
ESR1 mutations
ESR1-amplificatie
essential thrombocythenia and polycythemia vera
estetrol
ESTHER cohort study
esthesioneuroblastoom
esthetische uitkomst
estimating risk of pancreatic cancer in the general population
estradiol levels
estrogen monotherapy
ET
ET outcomes
ET with versus without CDK4 6 inhibitors
etirinotecan pegol
etnische diversiteit
ETP-ALL LBL
ETS
EU-regelgeving
EURECCA
Euro-E.W.I.N.G.99
Euro-Ski
EURO-SKI studie
EUROCARE-5
European cancer mortality
European Code against Cancer
Europese kankermortaliteit
EURTAC
EUTOS
EV-101 study
EV-201 study
EV-301 study
EV-assay
evaluation of adjuvant chemotherapy after neoadjuvant FOLFIRINOX
evaluation of hematuria
EVAN study
event order
everolimus
everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer
everolimus plus letrozole and metformin
everolimus plus octreotide
everolimus plus pazopanib
everyday clinical practice
evofosfamide
Ewing and Ewing-like sarcoma in adults
Ewing sarcoma
Ewing sarcoom
Ewing-2008
ex vivo IFNγ production
exceptional responder
EXCITE-studie
exemestaan
exemestaan plus everolimus
exemestane with or without enzalutaimde
exemstaan
exercise intervention in cancer patients
exercise versus usual care
exhaled breath tests
exogenous hormone use
exome sequencing-based screening
exosomal lncRNA-GC1
exosomen
expansie van fase 1-studie PCD4989g
Exploratieve analyse MARQUEE-studie
exposoom
exposure to occupational carcinogens in 195 countries
expressie stromagenen in CRC
EXPRESSION III-studie
expression of biomarkers
expression of insulin-like growth factor-1 receptor on CTCs
extended endocrine benefit
extended follow-up of PALOMA-2 study
EXteNET
ExteNET-studie
extension of aromatase inhibitor therapy
extensive stage
extensive stage small cell lung cancer
extensive-stage small cell lung cancer
extensive-stage small-cell lung cancer
external beam radiation therapy
external validation of risk calculators
extracapsular extension in sentinel node
extracorporeal photopheresis
extracranial chondrosarcoma
extracranial oligometastasis
extracranial oligometastatic breast cancer
extrahepatisch cholangiocarcinoom
extrameningeal primary SFT
extranodal natural killer T-cell lymphoma
extranodale extensie
extrapleural pneumonectomy
extrauterine disease
EZH2
FACE
facial nerve function
facial-aging app
facility volume
facilty volume and mortality
factors affecting sentinel node metastasis
factors associated with duration of diagnostic interval
factors associated with risk of progression
factors associated with vomiting control
factors influencing multidisciplinary tumor board recommendations
factors predicting invasive breast cancer recurrence
FAKTION study
FALCON
fall and fracture risk
false positive FIT
familair mammacarcinoom
familiaal colorectaalcarcinoom
familiaal risico
familiaire adenomateuze polyposis
familiaire adenomateuze popyposis
familial and hereditary cancer syndromes
familial platelet disorder
familiale adenomateuze polyposis
familiegeschiedenis
familiegeschiedenis prostaatkanker
family history
family history of breast cancer
family history of cancer
family history of OC and BC
family history-based screening
FaMRIsc study
fase 2-studie BOLERO-4
fase 2-studie BOLERO-6
fase 2-studie KEYNOTE-224
Fase 2-studie SWOG S0801
fase 3- studie DREAM
fase 3-studie AURA3
fase 3-studie BrighTNess
fase 3-studie COLUMBUS
Fase 3-studie CRITICS
fase 3-studie ETNA
fase 3-studie FATA-GIM3
fase 3-studie GEC-ESTRO
Fase 3-studie KEYNOTE-045
fase 3-studie METEOR
Fase 3-studie MONALEESA-3
fase 3-studie MONALEESA-7
fase 3-studie NETTER-1
Fase 3-studie PERSEPHONE
fase 3-studie PRODRIGE 9
Fase 3-studie SAKK 75 08
Fase 3-studie SWOG S9921
fase 3-studie TROG 05.01
fase 3-studies
FAST study
FAST-Foward noninferiority phase 3 study
fatal ICI-associated toxic effects
fatalisme
fatigue
fatigue in cancer patients
favorable histology Wilms tumor
FCR
FCT
FDA approval of novel cancer therapies between 2000 and 2016
FDA oncology drug approvals in 2018
FDA-approved novel oncology drugs
FDG-PET
FDG-PET CT
FDG-PET scanning
feasibility
febriele neutropenie
fecal and plasma short-chain fatty acdis
fecale immunochemische test
female and male breast cancer. global trends 1990-2017
female breast cancer risk
fentanyl
fentanyl sublinguale spray
fenylketonurie hyperfenylalaninemie
fermented dairy foods
fertiliteitspreservatie
fertility drugs
fertility preservation
fertility treatment
fertility-sparing surgery
FGFR pathway alterations
FGFRs
FH02 study
FHWT
FIA
FIGHTDIGO-studie
fijne motoriek
fijnstof
FIL-HD0801 study
Final OS results from SOLO2 study
Finale analyse FIRST-studie
finale analyse van GOG 240-studie
finale overlevingsresultaten van KEYNOTE-006
financial links
financiële toxiciteit
finasteride
fine-needle biopsy
FinXX-studie
FIR-studie
FIRE-3
FIRE-SCLC Cohort Study
firefighters
FIRES
first line therapy
first relapse B-ALL in children and AYAs
first-degree relatives of pancreas cancer patients
First-iGAP study
first-line atezolizumab
first-line atezolizumab plus chemotherapy
first-line azacitidine plus venetoclax
first-line bavacizumab plus trebananib without chemotherapy
first-line BV plus nivolumab
first-line carboplatin versus cisplatin
first-line carboplatin-paclitaxel with or without bevacizumab
first-line cemiplimab
first-line CHOP or R-CHOP
first-line cladribine with concurrent or delayed rituximab
first-line CLL treatment
first-line DADI trial
first-line dose-dense early postoperative intraperitoneal chemotherapy
first-line everolimus plus bevacizumab
first-line FOLFIRINOX
first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel
first-line gemcitabine-trastuzumab-erlotinib combination
first-line lorlatinib versus crizotinib
first-line mFOLFOX6 plus bevacizumab versus cetuximab
first-line nivolumab plus cabozantinib for advanced RCC
first-line NSCLC treatment
first-line osimertinib
first-line pazopanib
first-line pembrolizumab
first-line pembrolizumab for advanced NSCLC with low PD-L1 expression
first-line pembrolizumab monotherapy
first-line pembrolizumab plus R-CHOP
first-line quavonlimab (anti-CTLA-4) plus pembrolizumab
first-line R-CODOX-M R-IVAC chemotherapy
first-line radioembolization plus chemotherapy
first-line SRS versus WBRT
first-line sunitinib
first-line TKIs
first-line trastuzumab
first-line treatment
first-line treatment options
first-line Tumor Treating Fields plus chemotherapy
first-line venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
first-line versus second line daratumumab
first-relapse rhabdomyosarcoma
FIRSTANA-studie
fistula
FIT
FIT cohort
FIT screening
FIT-detection of advanced colorectal neoplasia
FIT-screening
fitheid
fitness
five miRNA-model
five-miRNA based classifier
five-year analysis
five-year outcome
five-year outcomes
five-year PROs
five-year survival outcomes
five-year survivors of adolescent and young adult cancer
five-year survivors of chldhood cancer
fixed duration of venetoclax-rituximab
fixed-duration MRD-guided approach
FKBPL
FL
FLAME trial
FLAURA study
FLAURA-studie
flavonoïden
flexibele sigmoïdoscopie
flexibele-sigmoïdoscopie
FLIPPER trial
Florence Trial long-term results
FLOT4 study
FLOT4-studie
FLT3-internal tandem duplication mutated AML
FLT3-ITD AML
FLT3-ITD positive AML
fluciclovine versus PSMA PET-CT
fludarabine
FLUOGLIO-studie
fluoropyrimidine therapy
fluoropyrimidines
fluoroscopie
fluorouracil-leucovorin
fluzoparib
FLYER study
FNMTC
focal adhesion kinase
focal boost
FOCUS-cohort
Fol-BRITe study
FOLFIRI
FOLFIRI plus cetuximab or bevacizumab
FOLFIRINOX
FOLFIRINOX salvage treatment
FOLFOX
FOLFOX4
FOLFOXIRI
FOLFOXIRI plus panitumumab
FOLFOXIRI-bevacizumab versus doublets-bevacizumab
foliumzuur
FOLL05-studie
folliculair lymfoom
follicular and other CD20+ non-Hodgkin lymphoma
follicular lymphoma
follow-up after discontinuation
follow-up after treatment cessation
Follow-up analyse van CheckMate 067-studie
follow-up analyse van JFMC34-0601
follow-up van overlevers
food insecurity in cancer survivors
forego medical care
formaldehyde
FOrMAT-studie
FoRT trial
FORUM study
fosaprepitant
fosaprepitant meglumine
fotofarmacologie
four-factor prognostic model
FOXA1-expressie
FOXA2
FOXC1
FP with or without oxaliplatin
FPD AML
fractionated gamma knife radiosurgery
fractionated stereotactic radiosurgery
fractionated stereotactic radiotherapy
fracturen
fractures
fractuurrisico
fragiele ouderen
fragiliteit
frequency and outcomes of brain metastases
frequent cystoscopy
FRESCO study
fresolimumab
front-line fludarabine-cyclophosphamide-rituximab
front-line ibrutinib for CLL patient populations not included in RESONATE-2
frontline dasatinib
frontline hyper-CVAD plus ofatumumab
frontline targeted therapy plus low-intensity chemotherapy
frontline therapy for AML in elderly patients
frontline treatment for pediatric AML
frontline treatments
fruit
fruit and vegetable consumption
fruquintinib
FSRT
FSS versus RS
FTD versus HD-MA
FTL3-mutatie
FUJI cohort
fulvestrant
fulvestrant plus palbociclib
fulvestrant versus AIs
functional outcomes
FUS-ERG and RUNX1-CBFA2T3
fusion gene
Fusobacterium nucleatum
fysieke activiteit
G-CSF support
G-CSFs
g-NETs
G84E
gain-of-function mutatie
gait speed
galactography
galblaascarcinoom
GALEN study
galeterone
gallium-68 labelled PSMA-11 PET
GALLIUM-studie
galunisertib
galwegcarcinoom
gamma knife radiosurgery
ganglioside vaccine for high-risk neuroblastoma
ganglioside-monosialic acid
ganitumab
GARD
garlic
gastric adenocarcinoma
gastric cancer
gastric cancer family history
gastric cancer risk
gastric gastroesophageal junction AC
gastric or gastro-esophageal junction cancer
gastric or gastroesophageal junction adenocarcinoma
gastric or gastroesophageal junction cancer
gastric or GEJ adenocarcinoma
gastritis
gastro-intestinale mucositis
gastro-intestinale stromale tumoren
gastro-oesofagaal adenomcarcinoom
gastroenteropancreatic neuroendocrine tumors
gastroesophageal adenocarcinoma
gastroesophageal cancer
gastroesophageal reflux disease
gastrointestinal bleeding
gastrointestinal stromal tumor
gastrointestinal stromal tumors
gastroïntestinale kanker
gastroïntestinale stromale tumoren
Gattelli
GAUDI
GBC
GBCA
GBM
GBM in elderly patients
GBS
GBSM
GBV-C
GC
GC GEJC
GC1008
GC4419
GCA
GCC
GCT
GCTB
GCTs
GD
GDP
GEC
GeDDiS-studie
gedifferentieerd schildkliercarcinoom
gedissemineerde tumorcellen
gefitinib
gefitinib alone or with chemotherapy
gefitinib continuation after progression
GEICAM 2003-11_CIBOMA 2004-01 study
GEICAM 2010-04 study
gelokaliseerd prostaatcarcinoom
GEM
GEM-1402 study
gemcitabine
gemcitabine plus adavosertib
gemcitabine plus cisplatin induction chemotherapy
gemcitabine with or without berzosertib
gemcitabine-eribulin combination
gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy
gemcitabineresistentie
gemetastaseerd mammacarcinoom
gemetastaseerd melanoom
gemetastaseerde borstkanker
gemetastaseerde borstkanker; trastuzumab
gemetastaseerde colorectaalkanker
gemtuzumab ozogamicin
gemtuzumab ozogamicine
GEN501 and SIRIUS final results
gender differences
gene expression profiles
gene expression profiling assay
gene variants and subsequent neoplasms
gene variants associated with increased cancer risk
geneesmiddelinteracties
Generations Study
genetic and clinical predictors
genetic factors
genetic prognostic and predictive factors
genetic testing
genetically defined renal tumors
genetically proxied inhibition of HMG-CoA reductase
genexpressie
genito-urinaire maligniteiten
genmethylering
genome sequencing
genome-edited donor-derived anti-CD19 CAR T cells for pediatric and adult B- ALL
genome-wide association study
genome-wide diet-gene interaction
genome-wide variants
genomic alterations
genomic analysis in NRG Oncology RTOG 9802
genomic biomarkers predicting anti-PD-(L)1 response
genomic correlates
genomic correlates of progression or response
genomic determinants of clinical outcomes
genomic identification of HRD
genomic profiling
genomic profiling of prostate cancers from met with African and European ancestry
genotoxic pks E. coli
genotyping lung adenocarcinoma
GENUINE trial
genvarianten
GEOMETRY mono-1 study
GEP-NETs
GeparNuevo analysis
GeparNuevo study
GeparOcto secondary analysis
GeparQuattro-studie
GeparSepto
GeparSepto long-term outcomes
GeparSixto trial
gepegyleerd liposomaal doxorubicine
geptanolimab
geptanolimab (GB226)
gerandomiseerde fase 2-studie PrE0102
GERD treatment
Gerecke
geriatirc patients
geriatric assessment impairments
geriatric comanagement
Geriatric Prognostic Indicator
germ cell tumors
germline BARD1 gene variants
germline BRCA PALB2 mutation
germline BRCA pathogenic variant
germline BRCA-mutated metastatic pancreatic cancer
germline BRCA1 2 mutation
germline BRCA2 mutations
germline genetic testing
germline mutaties
germline mutations
germline mutations in DNA repair genes
germline PALB2 pathogenic variants
germline pathogenic variants in 28 genes
germline predisposition gene mutations
germline variant status
germline variants in DNA repair genes
germline variants in natural killer cells
geserreerde poliepen
geslachtshormonen
gestation and birthweight of offspring
gestationele trofoblasttumor
GETNE-TRASGU study
GETUG-AFU 16 study 112-months follow-up
gevorderd cervixcarcinoom
gevorderd maag-adenocarcinoom
gevorderd melanoom
gevorderd niercelcarcinoom
gevorderde borstkanker
gevorderde maagkanker
geweichtsverlies
gezondheidsutiliteitsindex
gFOBT
GFR
GFR; niercelcarcinoom; urotheelcarcinoom
GHSG HD13-15 trials
GHSG HD17 study
GI adverse events
giant-cell tumor of bone
gilteritinib
GIMEMA-MMY-3006 trail
GIST
GK-SRS with or without EGFR-TKIs
GLARIUS-studie
glasdegib
GLASS study
Gleason score 9-10 prostate cancer
glembatumumab vedotin
glioblastoma
glioblastoma in poor perfomance status patients
glioblastoma multiforme
glioblastoma recurrence
glioblastoma with methylated MGMT promoter
glioblastoom
glioma
glioma risk
gliomas
gliomen
glioom
glitazonen
global burden of breast cancer
Global Burden of Cancer
global burden of cancer attributable to infections in 2018
Global Burden of Disease Study
global expanded access program
global retinoblastoma presentation analysis by national income level
global trends
glottic squamous cell carcinoma
glucocorticoid treatment
glucose lowering drugs
GLUT-
GLUT-14
glutathion-S-transferase P1
glycaan-gerelateerde genen
glypicaan-1
GM-CSF
GMMG-MM5 trial
GNCC
GnHRa
GnRH-agonist
GO
GO30140 study
GOG-0213 studie
GOG-0213 study
GOG-0218 final OS-analysis
GOG-0218 studie
GOG-0277
Golestan Cohort Study
gonadotropine
Google Translate
GORTEC 2007-01 studie
gosereline
GOYA-studie
graft failure
graft versus host disease
graft-versus-host disease
graft-versus-host disease prophylaxis
grain consumption and dietary fiber intake
GRASPA
GRECCAR 2-studie
GREEN study subgroup analysis
GRIFFIN study
grijpkrachtverlies
grip strength
groeicurves naevi
groeisnelheid
groenten
groentenconsumptie
grootcellig granulair lymfocytaire leukemie
grootcellig neuro-endocrien longcarcinoom
grootte van lymfekliermetastasen
gross-total resection
grote-korrel lymfocyten leukemie
growth hormone deficiency
growth rate of untreated hemangioblastomas
growth rates
GSK2857916
GTT
GU-toxiciteit
guadecitabine
guanylaatcyclase
GVAX pancreas
GVHD
GVHD prevention after haploidentical HCT
GVHD prophylaxis
GWAS
Gxplore-002 study
Gxplore-005 study
gynecological brain metastases
gynecologische maligniteiten
H. pylori
HA-WBRT + SIB for brain metastases
HA-WBRT + SIB versus conventional WBRT
haarverlies
hafnium oxide nanoparticle
HAI
HAIC
hairy cell leukemia
hairy-cell leukemie
hallmarks of cancer
HALO 202-studie
Ham-Wasserman lecture
Hamilton Fairley Award
hand-voet huidreacties
hand-voet syndroom
hand-voetsyndroom
HannaH study final analysis
haplo versus UD transplantation
haplo-HSCT
haplo-HSCT versus chemotherapy
haplo-identieke HSCT
haplo-SCT
haploidentical versus unrelated cord blood transplantation
haploidentical versus unrelated SCT
haploidentical; sibling; matched unrelated donor
HART
hartfalen
hartfalen na auto-HCT
HBOC
HBV-related HCC
HBV-related HCC risk
HBV-vaccinatie
HC
hcc
HCC expressing CD147
HCC in HBV- or HCV-infected patients
HCC overall survival
HCC with portal vein tumor thrombus
HCMV reactivation during radiochemotherapy
HCT
HCV
HD 0607 trial
HD IL-2
HD12 study
HD16 trial
HD18-studie
HD9 study
HDAC inhibition
HDL-cholesterol level and risk of hematologic malignancy
HDR-brachytherapie
head and neck cancer
head and neck cancer risk after hematologic cancer
head and neck cancer surgery during COVID-19 pandemic
head and neck procedures
head and neck squamous cell carcinoma
head en neck cancer
Head Start III
health care use
health literacy
health maintenance practices
Health Professionals Follow-up Study
health promotion among cancer survivors
health-related quality of life
healthy immigrant effect
healthy lifestyle
healthy older adults
heavily pretreated HR-positive HER2-negative metastatic breast cancer
heavily pretreated MBC
heavy smokers
hedgehog-signaalroute
heldercellig niercelcarcinoom
heldercellig ovariumcarcinoom
Helicobacter pylori
Helicobacter pylori treatment
HELIOS study
hematologic malignancies in older patients
hematologic malignant neoplasms
hematologische maligniteiten
hematopoietic cell transplantation
hematopoietic score predicts outcomes
hematopoietic stem cell transplantation
hematopoietic stem cell transplation
hematopoïetische celtransplantatie
hemispheric-specific clinical presentation
hemochromatosis HFE p.C282Y homozygosity
HEPAR PluS study
hepatectomy in academic versus community cancer center
hepatic artery infusion pump chemotherapy
hepatitis B virus infection
hepatitis B-virus
hepatitis C
hepatocallular carcinoma
hepatocellulair carcinoom
hepatocellular carcinoma
hepatocellular carcinoma with portal vein invasion
hepatospleen T-cel lymfoom
hepatotoxiciteit
hepatotoxicity
HER2
HER2 amplification
HER2 exon 20 insertions
HER2 expression discordance between primary and metastatic breast cancer
HER2 peptide vaccines for prevention of breast cancer recurrence
HER2 pro-oncogene signalering
HER2-amplified mCRC
HER2-directed therapies
HER2-expressie
HER2-expressing cancers
HER2-gedreven NSCLC
HER2-HER3 dimerization
HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy
HER2-mutant lung cancer
HER2-mutant metastatic cervical cancer
HER2-negatief mammacarcinoom
HER2-negatieve borstkanker
HER2-negatieve MBC
HER2-negative
HER2-negative BC
HER2-negative breast cancer
HER2-negative MBC
HER2-negative metastatic breast cancer
HER2-negative tumors
HER2-overexpressing breast cancer
HER2-positief mammacarcinoom
HER2-positief metastatisch mammacarcinoom
HER2-positieve borstkanker
HER2-positieve vroege borstkanker
HER2-positive ABC
HER2-positive ABC MBC
HER2-positive advanced breast cancer
HER2-positive and AR-positive advanced breast cancer
HER2-positive and biopsy-proven node-positive breast cancer
HER2-positive breast cancer
HER2-positive breast cancer brain metastases
HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab
HER2-positive breast cancer with brain metastases
HER2-positive EAC
HER2-positive early breast cancer
HER2-positive early breast cancer in elderly
HER2-positive esophagogastric cancer
HER2-positive gastric cancer
HER2-positive gastro-esophageal adenocarcinoma
HER2-positive localized breast cancer
HER2-positive MBC
HER2-positive metastatic breast cancer
HER2-positive metastatic breast cancer after ≥ 2 HER2-directed regimens
HER2-positive salivary duct carcinoma
HER2-scoringsysteem
HER2-screening
HER2-targeted CAR T cell therapy
HER2-targeted therapies
HER2-targeted therapy
HER2+ BC
HER2+ breast cancer
HER2CLIMB
HER2CLIMB randomized phase 2 study
HER2CLIMB study exploratory analyses
HER2DX model
HER3-mutant mammacarcinoom
HERA
herb and supplement use
HERBY-studie
herceptin
herceptin-biosimilar
herceptine
Heritage
HERO study
heropname
herpes zoster after autologous stem cell tranplantation
hersenmetastasen
hersenmetastasen mammacarcinoom
hersenmetastasering
hersenmicrobloedingen
hersentumoren
Heterocephalus glaber
heterogeneity between SEER counties
HF-WBI
HFSRT
HGG
HGS OC
HGSOC
hidradenitis suppurativa
HIFU
high hereditary breast cancer risk
high PD-L1 expressing NSCLC
high risk early breast cancer
high risk locally advanced rectal cancer
high risk melanoma
high risk of colorectal peritoneal metastasis
high RS
high sensitivity C reactive protein
high versus low dose lenalidomide maintenance after transplantation
high-dose chemotherapy
high-dose chemotherapy and 3D conformal radiation
high-dose cyproterone acetate
high-dose intensity-modulated chemoradiotherapy
high-dose-rate brachytherapy
high-grade brainstem gliomas
high-grade glioma
high-grade osteosarcoma of the extremities
high-grade prostate cancer
high-intensity focused ultrasound
high-intermediate and high risk early stage EC
high-mobility group box 1
High-molecular-mass hyaluronan
high-PD-L1 expressing NSCLC with brain metastases
high-risk ALL in children
high-risk AML
high-risk AML in remission
high-risk breast cancer
high-risk cancer surgery
high-risk DLBLC
high-risk early breast cancer
high-risk EBC
high-risk endometrial cancer
high-risk extremity trunk STS
high-risk features
high-risk HNC patients
high-risk localized gastrointestinal stromal tumor
high-risk locally advanced rectal cancer
high-risk low-grade glioma
high-risk luminal breast cancer
high-risk lymphoma
high-risk mature B-cell non-Hodgkin’s lymphoma in children
high-risk medulloblastoma in children
high-risk melanoma
high-risk neuroblastoma
high-risk oral squamous cell carcinoma
high-risk prostate cancer
high-risk resected melanoma
high-risk rhabdomyosarcoma
high-risk smoldering multiple myeloma
high-risk soft tissue sarcoma
high-risk stage 2 colon cancer
high-risk uveal melanoma
HIIT
HiLo trial
HIPEC
HIPEC + CS
histologic regression
histological biomarkers
histologische regressie
histology-tailored versus standard neoadjuvant chemotherapy
histopathologic features
history of use of statins and COX-2 inhibitors
HIV
HIV AIDS
HIV infection
HIV infection in elderly patients
HIV RNA
HIV-associated Kaposi sarcoma
HIV-infection
HL
HL diagnosis during pregnancy
HL-behandeling
HLA antigen mismatch
HLA-matched or alternative donors
HMAs for high-risk MDS or AML
HMIE versus open esophagectomy
hMPV
HMR 2.0
HNC
HNCs
HNSCC
HNSCC surgery
Hodgkin and non-Hodgkin lymphoma
Hodgkin lymfoom
Hodgkin lymphoma
Hodgkin lymphoma in children and adolescents
Hodgkin's lymfoom
Hodgkin’s lymphoma
hofd-hals Merkel celcarcinoom
hoge dosering chemotherapie
Hokusai VTE-Cancer studie
holmium-166 after lutetium-177-dotatate
home administration of trastuzumab
homeobox B13
homocysteïne
homologous recombination deficiency
hoofd hals squameus celcarcinoom
hoofd halscarcinoom
hoofd halskanker
hoofd-hals melanoom
hoofd-hals squameus celcarcinoom
hoofd-halscarcinoom
hoofd-halskanker
hoofdhuidkoeling
hoog-risico B-ALL
hoog-risico cervixcarcinoom
hoog-risico CML
hoog-risico melanoom
hooggradig sereus ovariumcarcinoom
horizontale transfer
hormonal therapy
hormonal therapy resistance
hormone-modulating breast cancer therapy
hormone-naïve metastatic prostate cancer
hormoonreceptor positieve borstkanker
hormoontherapie
hospital volume
hospitalisatie
hospitalization
hospitalization after adolescent and young adult cancer
hot flashes
HOVON 105 ALLG NHL 24
HOVON 105 study
How Long studie
HP SCC
HPC-SFT
HPD
HPTC
HPV
HPV ctDNA
HPV DNA in penile cancer and intraepithelial neoplasia
HPV DNA persistence
HPV load and genotype analysis
HPV status
HPV types
HPV types 16 18 in cervical precancers
HPV vaccination
HPV vaccine
HPV-16 18 vaccin
HPV-associated epithelial cancers
HPV-associated malignancies
HPV-associated oropharyngeal carcinoma
HPV-associated oropharyngeal squamous cell carcinoma
HPV-FOCAL trial
HPV-infectie
HPV-negative HNSCC
HPV-orofarynxcarcinoom
HPV-positive oropharyngeal cancer
HPV-positive oropharyngeal squamous cell cancer
HPV-related OPSCC
HPV-typen
HPV-vaccinatie
HPV+OPSCC
HPV16 18-positive advanced cervical cancer
HPV16-related cancerISA101
HR-deficiëntie
HR-NB
HR-NBL1 SIOPEN study
HR-NL81 SIOPEN
HR-positief mammacarcinoom
HR-positief metastatisch mammacarcinoom
HR-positive advanced breast cancer
HR-positive advanced postmenopausal breast cancer
HR-positive breast cancer
HR-positive breast cancer brain metastases
HR-positive early-stage breast cancer
HR-positive HER2 negative metastatic breast cancer
HR-positive HER2-negative advanced breast cancer
HR-positive HER2-negative advanced or metastatic breast cancer
HR-positive HER2-negative metastatic breast cancer
HR-positive HER2-negative metastatic breast cancer in older women
HR-positive HER2-positive advanced breast cancer
HR-positive metastatic breast cancer
HR-status
HR+ HER2- breast cancer
HR+ HER2- MBC
HR+ HER2- vroeg-stadium mammacarcinoom
HR+ HER2+ breast cancer
HR+ MBC
HRBOC
HRQoL
HRQOL in prostate cancer
HRT
HRT and breast cancer risk
HRT versus CRT
HSC
HSCT
HSCT-bijwerkingen
Hsp70
HT
hTERT-DCs
hu3F8
huidkanker
huidkankerscreening
huidmaligniteit
huidneoplasmen
huisartsenzorg
humaan papillomavirus
human equilibrative nucleoside transporter 1
human readers versus machine-learning algorithms
hybrid minimally invasive esophagectomy
hyperbaric oxygen therapy
hypercalcaemia of malignancy
hypercalcemie
hyperemesis gravidarum
hyperleukocytosis
hyperprogressive disease
hyperproliferatie van stamcellen
hypertensie
hypertension
hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery
hyperthermische intraperitoneale chemoperfusie
hypervascular intracranial tumors
HYPO-RT-PC study
hypodiploid ALL in children
hypofarynxcarcinoom
hypofractionated adjuvant radiotherapy
hypofractionated breast RT for 1 week versus 3 weeks
hypofractionated IMRT
hypofractionated postmastectomy radiotherapy
hypofractionated RT
hypofractionated SRS
hypofractionated SRT to the resection cavity
hypofractionated stereotactic radiotherapy
hypofractionated stereotactic radiotherapy after surgery for brain metastases
hypofractionated versus conventional RT
hypofractionated versus conventionally fractionated RT
hypofractionated versus conventionally fractionated whole-breast irradiation
hypomethylating agents
hyponatremie
HYPOR
HYPRO
I-131 labelled metuximab
i-ALCL
I-SPY 2 trial
I-SPY2 three-year follow-up analysis
iAMP21
IARC
IBC
IBCSG 23-01 trial
IBD
IBIS II
IBIS-I
IBIS-II trial 10 year follow-up
IBM Watson
IBR
ibrutinib
ibrutinib discontinuation
ibrutinib for CLL
ibrutinib plus fludarabine
ibrutinib plus palbociclib
ibrutinib plus venetoclax
ibrutinib versus ofatumamab
ibrutinib with or without ublituximab
ibrutinib-obinutuzumab-venetoclax combination
ibuprofen
ICARIA-MM study
ICARIA-MM subgroep analysis
ICB
ICBP SURVMARK-2 study
ICC
ICI for GBM
ICI therapy
ICI therapy in IBD patients
ICI treatment
ICI-associated neurotoxicities
ICI-related multisystem immune-related adverse events
ICI-related myocarditis
ICIs
ICIs for advanced cSCCs
ICIs for advanced non-small cell lung cancer
ICIs for advanced NSCLC in clinical practice
ICIs for cancer
ICIs for lung cancer or malignant melanoma
ICIs for melanoma
ICIs for melanoma in patients with preexisting autoimmune disease
ICIs for metastatic cancers in solid organ transplant recipients
ICIs for metastatic melanoma. early prediction of pseudoprogression
ICIs for metastatic renal and urothelial cancer
ICIs for non-small cell lung cancer
ICIs for NSCLC
ICIs plus chemotherapy
ICLL-07 FILO trial
ICLL07 FILO study
ICON6-studie
ICON8 study
ICON8-studie
ICPi
ICU-opname
idarubicine plus cytarabine plus nivolumab
iddEPC-studie
IDEA collaboration
IDEA-collaboration
idelalisib
IDH mutation
IDH-mutant lower-grade glioma and glioblastoma
IDH1-expressie
IDH1-mutant solid tumors
idiopathische membraneuze nefropathie
idiopatische MCD
Idylla
IELSG-19 studie
IELSG32-studie
IES
IFD
IFG
IFM 2009
IFN-onderhoudsbehandeling
IFRT
IGBT
IGF-1
IGF-1R expressie
IGF2-AS
IgM MGUS
IGT
IHCA
IHCC
IHGV mutational status
IIIA-N2 NSCLC
ijzersuppletie
IKFZ1-deletie
IKFZ1-deletion
IKZF1-deletie
IL-12 plasmid transfection
IL-6
IL-8
ILC
illness perception and outcomes in cancer
iLLUMINATE study
image-guided intensity modulated radiation therapy
Imaging
imaging surveillance
imaging-based prostate cancer screening
IMAJEM-studie
imatinib
imatinib after other multi-kinase inbitors
iMATRIX study
IMbrave 150 study
IMbrave150 study
imetelstat
IMiDs
imiquimod
immediate vs deferred cytoreductive nephrectomy
IMmotion 151 trial
IMmotion 151-studie
IMmotion151 trial
immune checkpoint blockade
immune checkpoint inbition for cancer
immune checkpoint inhibition
immune checkpoint inhibition for unresectable HCC
Immune Checkpoint Inhibitor
immune checkpoint inhibitor associated acute kidney injury
immune checkpoint inhibitor for NSCLC
immune checkpoint inhibitor induced pituitary dysfunction
immune checkpoint inhibitor rechallenge after irAE
immune checkpoint inhibitor therapy
immune checkpoint inhibitor trials
immune checkpoint inhibitor-induced colitis
immune checkpoint inhibitor-mediated diarrhea and colitis
immune checkpoint inhibitors
immune health
immune infiltration
immune markers of nivolumab response
immune microenvironment
immune response
immune-mediated diarrhea and colitis
immune-related adverse events
immune-related adverse events and efficacy of avelumab
immune-related meningitis
immune-related pneumonitis
IMMUNED study
immunocheckpoint blockade
immunochemottherapy
immunocompromised cancer patients
immunoglobuline lichte-keten amyloïdose
immunologically quiescent melanoma
immunophenotyping of TILs and PBLs
Immunoscore
immunosuppressive therapy for management of MDS
immunotherapy
immunotherapy after surgery of the primary tumor
immunotherapy for advanced non-small cell lung cancer
immunotherapy for advanced stage cancer
immunotherapy for EGFR ALK wild-type advanced NSCLC
immunotherapy for melanoma
immunotherapy for NSCLC
immunotherapy plus stereotactic radiotherapy
immunotherapy rechallenge
immunotherapy-related pruritus
immutherapy
immuuncheckpointremmers
immuunrespons
immuunsuppressie
immuuntherapie
IMPAC
IMPACT
impact of adjuvant regimes
impact of adjuvant therapies on outcomes
impact of advances in treatment
impact of age
impact of age at diagnosis on survival
impact of age on melanoma response to bevacizumab
impact of age on outcomes
impact of alcohol and smoking and FRP
impact of antibiotics
impact of antiviral therapy for chronic hepatitis C
impact of asparaginase discontinuation on outcome
impact of attending surgeon
impact of baseline body mass index
impact of biopsy frequncy on metastasis and mortality
impact of bone metastases
impact of BRAF V600E K mutation status
impact of breast cancer treatment on employment
impact of breast screening programme on mortality in England
impact of calcium channel blocker use
impact of centralization within hospital systems
impact of cisplatin-based chemotherapy on risk of metachronous contralateral disease
impact of concomitant PPIs on survival
impact of concurrent dexamethasone on clinical benefit
impact of conditioning intensity
impact of cumulative exposure to premenopausal obesity
impact of detailed family history
impact of diet
impact of disease stage
impact of EGFR mutation and ALK rearrangement
impact of epigenetics on association of aspirin use with mortality after breast cancer
impact of ER status on survival
impact of facility caseload
impact of follow-up time
impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response
impact of high TMB on response rates
impact of HIV infection
impact of hormone receptor status
impact of imaging intensity on survival after systemic therapy
impact of low-dose aspirin
impact of lower airway dysbiosis on progression
impact of metabolic syndrome
impact of moderate-to-vigorous intensity physical activity
impact of molecular subtypes on incidence and prognosis of CNS metastases
impact of optimizing diagnostic workup and reducing time to treatment
impact of overweignt and obesity
impact of patient age
impact of poverty
impact of pre-existing CVD on mortality
impact of pregnancy on genomic landscape
impact of primary tumor surgery
impact of prior CT or RT on efficacy of durvalumab for NSCLC
impact of prior or concurrent antibiotic therapy
impact of prior therapy
impact of race ethnicity
impact of race on outcomes
impact of race on outcomes of definitive RT
impact of radiation facility volume
impact of screening
impact of screening on OPE diagnosis
impact of solid cancer on in-hospital mortality
impact of stewardship program
impact of subtype on GKS outcomes
impact of surveillance
impact of treatment modality on performance of prognostic factors
impact of tumor size and high-risk features on chemotherapy benefit
impact on breast cancer incidence and mortality
impact on breast cancer risk
impact on CRC incidence and mortality
impact on functional age and mortality
impact on memory
impact on metastatic behavior and outcome
impact on OC risk in African American and White women
impact on outcome
impact on outcomes
impact on outcomes of durvalumab for NSCLC
impact on recurrence and survival
impact on sexual function
impact on short-term mortality
impact on survival
impact on survival and recommended treatment intensity
IMPACT program
IMPACT-studie
IMPACT2
IMpassion031 trial
IMpassion130 study
IMpassion130 study updated results
IMpassion130 trial
IMPATTO study
implications of minimal residual disease detection
IMPORT LOW study
IMpower110 study
IMpower130 trial
IMpower132 trial
IMpower133 Study
IMpower133 updated analyses
IMpower150 study
IMpower150 trial safety and PROs
IMpower150-studie
IMPRESS-studie
IMPROVE study
IMPT
IMRT
IMRT alone
IMspire150 trial
IMT
IMvigor130 study
IMvigor211-studie
in situ mammacarcinoom
in utero chemotherapy exposure
in-hospital mortality
incidence
incidence and mortality in England
incidence and mortality of second primary cancers
incidence and outcomes
incidence and outcomes of lung cancer
incidence and predictors of diabetes mellitus
incidence and survival among solid organ transplant recipients
incidence and survival in the USA 1973-2015
incidence of and mortality from malignancies after CIN treatment
incidence of hypothyroidism
incidence of pneumonitis
incidence of relapse
incidence of T790M mutation in cfDNA
incidence of thyroid cancer in WTC-exposed rescue workers
incidence of vulvar precancerous lesions and cancer
incidence of young adult cancers in Canada
incidence trends
incidence trends of breast cancer molecular subtypes by age and race in the US
incident cancer
incident cancer risk
incident cardiovascular events
incident type 2 diabetes duration
incidental pulmonary embolism in cancer patients
incidentally detected lung nodules
incidentally found pediatric brain tumors
incidentie
incidentie mammacarcinoom USA
incomplete pregnanacy
increased α-fetoprotein
increasing dose intensity of chemotherapy
INDAR
independence
indeterminate pulmonary nodules
individual oncogenic HPV types
individual patient-level analysis
individualised axitinib regimen
indolent lymfoom
indolent mammacarcinoom
indoor tanning
Indoor tanning industry
inductie-chemoradiatie
inductiechemotherapie
induction chemotherapy
induction chemotherapy for AML
infants
infectie
infigratinib
inflammatie
inflammation cascade
Inflammatoir mammacarcinoom
inflammatoire voeding
inflammatory bowel disease
Inflammatory breast cancer
inflammatory markers
influenza vaccination
influenza vaccine effectiveness among cancer patients
influenzavaccinatie
infradiaphragmatic disease
inhaled corticosteroids
INHANCE-consortium
iNHL
iniparib
INITIATE study
iNNOVATE
iNNOVATE-studie
innovations in therapy
InnovaTV 201 study
INO-VATE studie
inoperable endometrial cancer
inotuzumab ozogamicin
inpatient versus outpatient administration
INSIGHT-studie
inspanning
Institute of Cancer Research
insulin resistance
insulin-like growth factor
insulin-like growth factor -1
insulinemie
insulineresistentie
intake of one-carbon metabolism-related micronutrients
intake of whole grains and dietary fiber
INTEGRATE
integrated palliative and oncology care
INTELLANCE 2 study
intellectual outcomes
INTENS-studie
intense androgen deprivation before prostatectomy
intensieve chemotherapie
intensity of diagnostic evaluation
intensity-modulated radiation therapy
intensive therapy
inter- and intra-laboratory variation
InterAAct
Intergroup Exemestane Study
interim OS analysis of MONARCH 2
interim PET
interim PET CT predicts PFS
intermediate recurrence score
intermediate- or high-risk GIST
intermediate-risk AML
intermediate-stage hepatocellular carcinoma
intermittent nivolumab
intermittent versus continous PEG-asparaginase
intermitterende claudicatie
internal mammary and medial supraclavicular irradiation
International Breast Cancer Intervention Study I
International Childhood Cancer Cohort Consortium
International Male BC Program
International Prognostic Index
International Prognostic Score
international variation in radiation dose
internet-steunprogramma's
interruption or noncompletion of chemoradiotherapy
interstitial lung disease induced by HER2-targeting therapy for MBC
interval breast cancer
interval cancers
interval versus screening-detected breast cancers
interval-compressed VDC IE-chemotherapy
intervalcarcinomen
intervals to diagnosis
intra-tumor heterogeniteit
intracraniaal ependymoom
intracranial meningioma
intracranial metastatic disease
intractable serous ascites
intraductale papillaire mucineuze neoplasie
intraductale papillaire mucineuze neoplasmen
intrahepatic cholangiocarcinoma
intrahepatic cholangiocarcinoma risk
intrahepatisch cholangiocarcinoom
intraoperative peritoneal lavage
intrapatient heterogeneity in enzalutamide response
intraperitoneale chemotherapie
intratumoral F. nucleatum
intratumorale genetische heterogeniteit
intratumorale genoomdiversiteit
intrauterine devices
intravitale microscopie
intrinsic subtype analysis of BOLERO-2
intrinsiek subtype
intrinsieke subtypes
intrinsieke subtypes mammacarcinoom
invasieve borstkanker
invasive breast cancer
invasive cervical cancer
invasive fungal infections
invasive lobular carinoma of the breast
invasive melanoma
invasve breast cancer and breast cancer mortality after screen-detected DCIS
INVICTUS trial
invloed behandelcentrum op overleving
involvement of dentists
ioniserende straling
iontoforese
IORT
IOTA5 study
IP1-PROSTAGRAM study
ipatasertib
IPD meta-analysis
IPH4102
ipilimumab
ipilimumab plus nivolumab
ipilimumab versus pembrolizumab
IPMN
ipsilateral breast event
IPTT
irAEs
IRd
IRE
irinotecan
irinotecan dose
irinotecan plus cetuximab with or without vemurafenib
IRIS
isatuximab
iscocitraatdehydrogenase
isocitraatdehydrogenaseremmer
isocitrate dehydrogenase 1-mutated glioma
isocitrate dehydrogenase wild-type glioblastoma in young adults
isoflavone intake
isolated breast pain
isolated synchronous colorectal peritoneal metastases
Italiaanse cultuur
ITOMIC-001 studie
IV versus IP chemotherapy plus bevacizumab
IVC filters
IVF
IVIG for HG
ivosidenib
ivosidenib plus azacitidine
IVY study
IWDD
ixazomib
ixazomib maintenance
ixazomib of placebo toegevoegd aan lenalidomide-dexamethason
J-ALEX studie
JACC-studie
JACCRO CC-08 study
JACCRO GC-07 study
JACOB study
JAKARTA-2 studie
jandus
Janus Cohort
JAVELIN Bladder 100 study
JAVELIN Lung 200 study
JAVELIN Merkel 200 study
JAVELIN Merkel 200-studie deel B
JAVELIN ovarian cancer cohort
JAVELIN Renal 100-studie
JAVELIN Renal 101 study
JAVELIN Renal 101 trial second interim analysis
JAVELIN Solid Tumor studie
JAVELIN Solid Tumor study mUC cohort two-year follow-up
JAVELIN Solid Tumor Study NSCLC cohort
JAVELIN Solid Tumor trial
JAVELIN Solid Tumor trial mesothelioma cohort
JCOG0203 trial
JCOG0504-studie
JCOG0910-studie
JCOG0912 study
JCOG1001-studie
JCOG1007 study
JFMC37-0801 study
JGO
job-exposure matrices
jodium-131
joint replacement. B-cell neoplasms
JPHC nested case-control study
JULIET trial
JULIET-studie
JVDL study
KAMILLA exploratory analysis
kanker
kanker bij kinderen
kanker-immunotherapie
kankerchirurgie
kankerincidentie
kankermortaliteit
kankermortaliteit 2015
kankerpijn
kankerrisico
kankerrrisico
kankersterfte
kankersubtypes
KATE2 study
KATHERINE phase 3 study
KATHERINE study
katheter
KC
KDD
KdD versus Kd
keratinocytcarcinoom
keratinocyte carcinoma
Keratinocyte Carcinoma Chemoprevention Trial
keratinocyte carcinomas
kerncentrales
ketotifen
KEYNOTE-001
KEYNOTE-001 (secundaire analyse)
KEYNOTE-001 study
KEYNOTE-006 study
KEYNOTE-010
KEYNOTE-010 study
KEYNOTE-012
KEYNOTE-013 and -170
KEYNOTE-017 study
KEYNOTE-020
KEYNOTE-021
KEYNOTE-021 cohort G
KEYNOTE-021 study
KEYNOTE-022 study
KEYNOTE-024
KEYNOTE-028
KEYNOTE-028 and -158
KEYNOTE-028 and -158 pooled analysis
KEYNOTE-028 and -158 studies
KEYNOTE-028 studie
KEYNOTE-028 study
KEYNOTE-029
KEYNOTE-029 Part 1B long-term follow-up
KEYNOTE-029 studie
KEYNOTE-040 study
KEYNOTE-040 study HRQOL analysis
KEYNOTE-042 study
KEYNOTE-045
KEYNOTE-048 study
KEYNOTE-052 long-term oucomes
KEYNOTE-052 studie
KEYNOTE-055
KEYNOTE-059 studie
KEYNOTE-061 studie
KEYNOTE-062 phase 3 study
KEYNOTE-086 cohort A
KEYNOTE-086 cohort B
KEYNOTE-087
KEYNOTE-100 study
KEYNOTE-146 study
KEYNOTE-158 study
KEYNOTE-164
KEYNOTE-164 studie cohort B
KEYNOTE-177 study
KEYNOTE-180 study
KEYNOTE-181
KEYNOTE-181 study
KEYNOTE-189 studie
KEYNOTE-189 study
KEYNOTE-199 study
KEYNOTE-240 study
KEYNOTE-355
KEYNOTE-355 trial
KEYNOTE-407
KEYNOTE-407 final analysis
KEYNOTE-407 study
KEYNOTE-426 extended follow-up
KEYNOTE-426 study
KEYNOTE-427 cohort B
KEYNOTE-427 study cohort A
KEYNOTE-427 study cohort B
KEYNOTE-522 study
KEYNOTE-598
KEYNOTE-604
KEYNOTE-629 study
Khorana-score
Ki-67
Ki67
kidney cancer
kidney stones and risk of RCC and UTUC
kidney transplant recipients
kiemceltumor
kiemceltumoren
kinaseremmers
kinderkanker
KIT
klachten aromataseremmers
KLASS-01 studie
KLASS-02-RCT
klassiek Hodgkin lymfoom
klein lymfocytair lymfoom
kleincellig longcarcinoom
kleincellig prostaatcarcinoom
kleincellige longkanker
kliernegatief mammacarcinoom
klierpositief mammacarcinoom
KMT2A-rearranged ALL in infants
Know Your Tumor registry trial
koffie
koffieconsumptie
kosten behandeling HER2-positief MBC
kosten van gezondheidszorg
kosteneffectiviteit hematologische middelen
kosteneffectiviteit screening
KP-BSI
KRAS
KRAS G12C mutation
KRAS mutation
KRAS wild-type mCRC
KRAS-G12C mutant NSCLC
KRAS-mutatie
KRAS-mutaties
KRd versus VRd for newly diagnosed multiple myeloma
KRISTINE study
KRISTINE-studie
KRYSTAL -1 study
KRYSTAL-1 study
KS
KSHV-transmissie
KTE-X19 CAR T-cell therapy
kwaliteit van leven
L-COSY
L-MIND study
LA-CSCC
LA-ESCC
LA-HNSCC
LA-NSCLC
laag-moleculairgewicht heparine
laag-vet voeding
laaggradig glioom
laaggradig niet-spierinvasief urotheelcarcinoom
laaggradig sereus ovarium- of peritoneaal carcinoom
laat recidief coloncarcinoom
LABC
labeled sodium fluoride PET CT
LACE-Bio studies
LACE-Bio-II study
LACE-studie
LAcSCC
LADG
LADG versus ODG
LAFA-studie
LAHNC
LAM
LAM-SA 2007 study
LAMIS
LAN
Lancet Haematology
Lange-termijn analyse van SBG 2004-1 studie
lange-termijn follow-up van KEYNOTE-001
lange-termijn uitkomsten GeparQuinto
langerhanscel histiocytose
LAP07
LAPACT study
laparoscopic versus open distal gastrectomy
laparoscopic versus open gastrectomy
laparoscopic versus open resection
laparoscopic versus open surgery
laparoscopic versus open total gastrectomy
laparoscopie
laparoscopische chirurgie
laparoscopische hysterectomie
laparoscopische ingreep
laparoscopische resectie
lapatinib
LAPC
LAPC-1 trial
LARC
large B-cell lymphoma
large brain metastases
large skull base meningiomas
larotrectinib
laryngectomy
laryngectomy outcomes
larynxcarcinoom
larynxkanker
larynxpreservatie
Lasker Award
late bone marrow relapse of B-cell ALL in children
late cardiac adverse events
late distant recurrence
late lower cranial neuropathy
late mortaliteit
late mortality in the North American CCSS versus the UK BCCSS
late outcomes
late recurrence
late recurrence after liver resection
late toxicity of moderately hypofractionated PBT versus IMRT
late-onset anorectal disease
Lateral Node Study
LATITUDE study
LATITUDE-studie
LAVC
lazertinib
LC
LCH
LCL161
LCNEC
LCS-6 KRAS
LDCT lung cancer screening
LDH response as prognostic biomarker
LE
LEA-studie
LEBS
leefstijl
leefstijl-geassocieerde maligniteit
leefstijlfactoren
leefstijlinterventies
leeftijd
left anterior descending coronary artery radiation dose
left lung cancer
left ventricular global longitudinal strain
leighl
leiomyomatose
leiomyosarcoom
leisure-time physical activity
lenalidomide
lenalidomide maintenance
lenalidomide maintenance after autologous hematopoietic stem cell transplantation
lenalidomide maintenance versus observation
lenalidomide plus rituximab
lenalidomide with or without EPO alfa
lenvatinib
lenvatinib plus pembrolizumab
lenvatinib plus pembrolizumab or everolimus versus sunitinib
lenvatinib plus pembrolizumab salvage therapy
leptomeningeal disease
leptomeningeal disease in metastatic melanoma patients
leptomeningeal disease recurrence
leptomeningeal metastases
leptomeningeal metastases from NSCLC
leptomeningeale ziekte
letrozol
letrozole
letrozole for early breast cancer
letrozole maintenance therapy
letrozole with or without bevacizumab
leucine-rich repeating G-protein-coupled receptor 5
leukapheresis
leukemia
leukemia cutis
leukemie
leukemie in kinderen
leukocyt-telomeerlengte
leukocytenattractie
leukocytosis
leumie
levensverwachting
levercarcinoom
levercelcarcinoom
levercelkanker
leverfunctie
leverkanker
levermetastasen
levofloxacin prophylaxis of infection
Leydig cell function
LFS
LGG
LGG before one year of age
LGSC
LGSOC
Li-Fraumeni syndrome
Li-Fraumeni syndroom
liberal versus restrictive thresholds
LIBRETTO-001 study
lichaamsgewicht
lichaamslengte
lichaamsomvang
lichaamsvet
lichaamsvetgehalte
lichte keten-geassocieerd Fanconi syndroom
lidocaïne
lieu
lifastuzumab vedotin
life expectancy free from major chronic diseases
life expectancy of adult survivors of childhood cancer diagnosed between 1970 and 1999
lifestyle
lifestyle factors
lifestyle factors and risk of MPN
lifestyle intervention
lifirafenib
ligating veins first versus arteries first
light-chain amyloidosis
limited-stage diffuse large B-cell lymphoma
limited-stage small cell lung cancer
LINC00472
lincRNA
linked color imaging
linsitinib
lip-SCC
LIPI
lipophilic statin use
lipophilic statins
liposarcoom
lipoxygenases
liquid biopsy
liquid biopt tracking in surveillance
liquide biopten
liso-cel
Listeria expressing mesothelin
LITT
liver cancer
liver cancer mortality
Liver Cancer Pooling Project
liver cancer risk
liver metastatic breast cancer
liver resection for malignancy
liver surgery for primary liver cancer
liver transplantation after tumor downstaging
liver-directed local therapy
LLPCa
LM
LMB-2
LMR
LNC-PATH score
lncRNAs
lobectomie
lobectomy
lobulair carcinoom in situ
lobulair mammacarcinoom
lobular breast cancer
local consolidative therapy
local control
local failure
local recurrence
local recurrence after transanal TME
local therapy
localized GIST
localized high-risk prostate cancer
localized OPSCC
localized pancreatic cancer
localized PCa
localized PDAC
localized prostate cancer
localized renal cell carcinoma
localized small bowel adenocarcinoma
localized versus advanced stage
localizing recurrent prostate cancer
locally advanced BCC
locally advanced bladder cancer
locally advanced breast cancer
locally advanced cancer
locally advanced cervical cancer
locally advanced esophageal cancer
locally advanced gastric cancer
locally advanced head and neck squamous cell carcinoma
locally advanced HER2-negative breast cancer
locally advanced intrahepatic cholangiocarcinoma
locally advanced large cell neuroendocrine carcinoma of the lung
locally advanced laryngeal cancer
locally advanced lung cancer
locally advanced non-small cell lung cancer
locally advanced NSCLC
locally advanced or metastatic melanoma
locally advanced or metastatic non-squamous NSCLC
locally advanced or metastatic sarcoma
locally advanced pancreatic cancer
locally advanced pancreatic cander
locally advanced pancreatic neuroendocrine tumors
locally advanced prostate cancer
locally advanced rectal cancer
locally recurrent brain metastases
locally recurrent NPC
locally recurrent or metastatic HER2-positive breast cancer
locatie
locatie van overlijden
locoregionaal recidief
locoregional recurrence
locoregional recurrence of breast cancer
Locoregional recurrent rhabdomyosarcome
locoregionale behandeling
locoregionally advanced HNSCC
LOGICA trial
LOH
lokaaal-gevorderd rectumcarcinoom
lokaal gevorderd prostaatcarcinoom
lokaal gevorderd rectumcarcinoom
lokaal recidiverend mammacarcinoom
lokaal-gevorderd hoofd-halscarcinoom
lokaal-gevorderd metastatisch mammacarcinoom
lokaal-gevorderd rectumcarcinoom
lomustine
lomustine plus temozolomide
loncastuximab tesirine
Long Island Breast Cancer Study Project
long-term antiandrogen therapy
long-term cancer risk
long-term cause-specific mortality
long-term cerebrovascular changes
long-term consequences
long-term CRC risk
long-term CRC risk after screen detected adenoma
long-term disease-free breast cancer survivors
long-term follow-up
long-term follow-up BIG 1-98 trial
long-term follow-up KEYNOTE-012
long-term health outcomes
long-term IHD risk
long-term impact
long-term mental health service utilization
long-term neurocognitive and psychosocial outcomes
long-term outcomes
long-term responders
long-term results
long-term results OlympiAD study
long-term risk of endocrine and metabolic diseases
long-term risk of hospitalization
long-term risk of infections
long-term somatic disease risk
long-term survival
long-term survivors NHL
long-term survivors of advanced melanoma treated with checkpoint inhibitor
long-term survivors of childhood cancer
long-term survivors of cisplatin for testicular cancer
long-term survivors of IDH-wildtype glioblastoma
long-term survivos of childhood cancer
long-term thyroid cancer risk
longadenocarcinoom
longcarcinoom
longer intervals after negative low-dose CT result
longfunctie
longitudinal analysis of fatigue and anxiety and quality of life
longitudinal analysis of HRQOL
longkanker
longkanker-screening
longkankerchirurgie
longkankerscreening
longmetastasen
LORELEI study
lorlatinib
lorlatinib after second-generation ALK TKI
lorlatinib versus crizotinib
loss of CEACAM1-expression
loss of heterozygosity 1p and 16q
loss of life expectancy
LOTUS-studie
low cT3 4 rectal cancer
low dose radioiodine ablation
low grade and anaplastic glioma
low grade glioma
low-dose aspirin
low-dose aspirin use
low-dose bisphosponates or denosumab
low-dose erlotinib
low-dose metronomic versus conventional chemotherapy
low-dose tamoxifen
low-grade glioma
low-grade glioma in children
low-grade upper tract urothelial carcinoma
low-intensity chemotherapy
Low-PV study
low-risk BD-IPMNs
low-risk CRC symptoms
low-risk prostate cancer
low-risk PTC
lower extremity lymphedema
lower-risk MDS
LP
LPHL
LPL
LPPG
LPS
LR-HL
LRBC
LRC
LRR
LS
LS SCLC
LS-SCLC
LSCC
LTL
LTLD
LUAD
LUME-Meso studie
luminal B
luminal B breast cancer
lumpectomy for early breast cancer
LUN 14-179 study
LUNA-studie
lung adenocarcinoma
lung adenocarcinoma brain metastases
lung adenocarcinoma with CNS metastases
lung and colorectal cancer
lung cancer
lung cancer incidence in young women versus young men in 40 coutnries
lung cancer mortality
lung cancer resection
lung cancer risk
lung cancer screening
lung cancer screening efficacy
lung cancer surgery
lung cancer survival
lung cancer survivors
lung nodule progression to cancer
Lung-MAP SWOG S1400
LUNGSTAR
LuPSMA
LuPSMA-studie
lurbinectedin
lurbinectedine
luspatercept
lutathera
lutetium-177 PSMA-617 versus cabazitaxel
LUX-Lung3; LUX-Lung6
LV-V5
LY3039478
LY3127804 with or without ramucirumab
lycopeen
LYM-3002
LYM-3002 study
LyMa-101 study
lymfadenectomie
lymfekliermetastasen
lymfeklierpositiviteit
lymfoblastisch non-Hodgkin lymfoom
lymfocyten
lymfocyteninfiltratie
lymfoedeem
lymfoïde neoplasie
lymfoom
lymph node burden
lymph node macrometastases
lymph node ratio
lymphadenectomy
lymphatic versus hematogneous dissemination
lymphaticovenous anastomosis
lymphedema
lymphocyte doubling time in CLL
lymphoma
lymphoma patients aged ≥85 years
Lymphome Malin de Burkitt chemotherapy
lymphopenia
lymphoscintigraphy
Lynch syndrome
Lynch syndrome associated cancers
lynch syndroom
Lynch syndrooom
LYRA study
M-trap
MA.17R
MA.17R-studie
MA.27
maag maag-slokdarmovergangkanker
maag-slokdarmadenocarcinoom
maagadenocarcinoom
maagcarcinoom
maagkanker
MaBC
MabEase-studie
MABLE-studie
MACBETH-studie
machine-learning-directed clinical evaluation of RT and CRT patients
MACRO2 TTD study
MAESTRO study
Magee Equation 3
MAGIC-studie
magnesium
magnesiuminname
MAIA study
MAIA trial
main-duct intraductal papillary mucinous neoplasms
maintenance
maintenance pembrolizumab after first-line chemotherapy
maintenance rituximab
maintenance therapy
maintenance treatment
maintenance with or without pembrolizumab
maitenance chemotherapy
MAJA study
MAJA-studie
major head and neck surgery
MALDI-MS
male BRCA mutation carriers
male breast cancer
male germ cell cancer treatment
male pattern baldness
male sex disease-specific mortality
MALE study
male-pattern baldness
malignant glioma
malignant melanoma
malignant mesothelioma
malignant pleural disease
malignant pleural effusion
malignant pleural mesothelioma
maligne ascites
maligne glioom
maligne pleura mesothelioom
maligne pleuraal mesothelioom
Malmö Breast Tomosynthesis Screening Trial
Malmö Diet and Cancer Study
malnutrition in older adults with gastrointestinal malignancies
MALT lymfoom
MALT-IPI
MALT-lymfoom
mamacarcinoom
mammacarcinoom
mammacarcinoom in mannen
mammacarcinoom mannen
mammacarcinoom; SABCS 2015
mammacarcinoom. lichaamsgewicht
mammacarcinoomscreening
mammacarcinooom
mammacarcionoom
mammacarcioon
MammaPrint
MammaPrint-assay
mammografie
mammografiescreening
mammographic surveillance in young women
mammography
mammography breast cancer screening in high-risk males
mammography screening
MAN
management and outcomes
managing oral complications of oral cavity and oropharyngeal cancer
mannen
Mannuci
mantelcellymfoom
mantle cell lymphoma
MAPS IFCT-GFPC-0701 study
MAPS2-studie
MARCH
margetuximab
margetuximab plus pembrolizumab
marginaal zone lymfoom
marginal zone lymphoma
MARIANNE study final results
MARIE study
MARIE-cohort
marihuana
marijuana use
marital status
marizomib
marker borstkanker
MARQUEE study
MARS mutation-adjusted risk score
masitinib
MasSpec Pen
mastectomie
mastectomy versus lumpectomy plus RT
matched sibling donor transplantation
matched therapy
maternal and fetal outcomes
maternal breast cancer risk
MATISSE-studie
MATRix induction
matrix metalloproteïnase-8
MAVORIC study
MAVORIC-studie
MaxRP
MaxRT
MBC
MBI
MBL
MBMs
MCC
MCC-Spain follow-up study
MCL
MCL in older patients
mCRC
mCRC extremes of survivorship
mCRPC
mCRPC in DDRmut patients
mCSPC
MD
MDS
MDS and sAML
MDS or AML
MDTB
meat consumption
meat intake
mebendazol
mechanisms of resistance to BRAF-targeted therapy
MED10562
MEDALIST study
median 15.7 years follow-up
medical decision-making capacity
medication interactions
medication-related osteonecrosis of the jaw
MEDIOLA study
medische marihuana
mediterrane voeding
medium-sized brain metastases
medium-throughput drug screening
MEDOCC
medullair schildkliercarcinoom
medullair thyroïdcarcinoom
medulloblastoma
medulloblastoma subgroups
medulloblastoom
meeroken
MEI
MEK- plus AKT-remming
MEK-remmers
MEK-remming
Mel-Ipi-Rx study
melanoma
melanoma brain metastases
melanoma brain metastasis
melanoma in adolescents and young adults
melanoma in children and adolescents
Melanoma Institute Australia nomogram
melanoma of unknown primary
melanoma with rare BRAF mutations
melanoom
melanoom-geassocieerde leucoderma
melanoom-mortaliteit
melanoomrisico
melatonine
MelBase French cohort
melfalan
melflufen plus dexamethasone
melkconsumptie
men with germline BRCA1 and BRCA2 pathogenic variants
MEN1
Mendelian randomisation analysis
meningioma
meningioma risk factors
meningioom
menopausal hormone therapy
menopausal hormone therapy options
menopauzale hormoontherapie
mental health
mental health disorders
mental health of mothers and siblings
mentale stoornis
Merkel celcarcinoom
Merkel cell carcinoma
Merkelcelcarcinoom
MESCC
mesothelin-targeted CAR T cells
mesothelioom
mestcel-neoplasmata
MET exon 14 altered lung cancer
MET exon 14-altered NSCLC
MET exon 14-mutated or MET-amplified NCSLC
MET-amplificatie
MET-driven metastatic papillary RCC
meta-analysis
meta-analysis of outcomes
meta-analysis of studies of immunotherapy for NSCLC
metabole gezondheid
metabolic dysregulation
metabolic health
metabolic syndrome
metabolic syndrome biomarkers
metabool syndroom
metachronous contralateral testicular cancer
metastase
metastasectomie
metastasering
metastasevrije overleving
metastasis sites
metastasis-directed therapy
metastasis-free interval
metastatic brain tumors
metastatic breast cancer
metastatic breast cancer in BRCA-mutated patients
metastatic breast cancer in geriatric patients
metastatic cancer
metastatic cardiophrenic lymph nodes
metastatic castration resistant prostate cancer
metastatic castration-resistant prostate cancer
metastatic castration-sensitive prostate cancer
metastatic clear cell RCC
metastatic colorectal cancer
metastatic colorectal cancer cetuximab plus FOLFOX-4
metastatic colorectal cancer in older vulnerable patients
metastatic CRC and other solid tumors with KRAS G12C mutation
metastatic endometrial cancer
metastatic esophagastric cancer
metastatic esophageal cancer
metastatic esophagogastric adenocarcinoma
metastatic esophagogastric cancer
metastatic gastric cancer
metastatic gastric or gastroesophageal junction cancer
metastatic gastric or junctional adenocarcinoma
metastatic gastrointestinal stromal tumors
metastatic gastrointestinal tract cancer
metastatic HER2-positive breast cancer
metastatic hormone-sensitive prostate cancer
metastatic intrahepatic cholangiocarcinoma
metastatic melanoma
metastatic melanoma and NSCLC
metastatic Merkel cell carcinoma
metastatic MSI-H dMMR CRC
metastatic mucosal melanoma
metastatic nasopharyngeal carcinoma
metastatic non-small cell lung cancer
metastatic non-squamous NSCLC
metastatic nonsquamous NSCLC
metastatic osteosarcoma
metastatic pancreatic adenocarcinoma
metastatic pancreatic cancer
metastatic pancreatic ductal adenocarcinoma
metastatic papillary renal cell carcinoma
metastatic papillary thyroid cancer
metastatic prostate cancer
metastatic renal cell carcinoma
metastatic soft tissue sarcoma in patients aged 60 years or older
metastatic spinal canal compression
metastatic squamous cell carcinoma of head and neck
metastatic squamous NSCLC
metastatic triple-negative breast cancer
metastatic urothelial carcinoma
metastatic uveal melanoma
metastatisch castratieresistent prostaatcarcinoom
metastatisch cervixcarcinoom
metastatisch colorectaalcarcinoom
metastatisch colorectaalkanker
metastatisch colorrectaalcarcinoom
metastatisch heldercellig niercelcarcinoom
metastatisch maagcarcinoom
metastatisch mammacarcinoom
metastatisch melanoom
metastatisch niercelcarcinoom
metastatisch niet-castratieresistent prostaatcarcinoom
metastatisch pancreas ductaal adenocarcinoom
metastatisch pancreascarcinoom
metastatisch PDAC
metastatisch potentieel
metastatisch prostaatcarcinoom
metastatisch squameus celcarcinoom van hoofd en hals
metastatische borstkanker
metastatische botziekte
metastatische castratieresistente prostaatkanker
metastatische colorectaalkanker
metastatische niet-kleincellige longkanker
metastatische prostaatkanker
metastatische triple-negative borstkanker
METEOR
METEOR-studie
metformin
metformin plus CRT
metformin plus irinotecan
metformin use
metformine
methionine
methotrexate neurotoxicity
metronome chemotherapie
metronomic methotrexate-celecoxib-erlotinib
METROS study
MF
mFOLFOX6
mGCT
MGPT
MGUS
MHD
mHNSCC
mHSPC
MHSs
MHT
MIBC
MIC-1
microductectomy
microRNA-203
microRNA-371a-3p test
microRNA-classifier
microRNAs
microsatelliet-instabiele kanker
microsatellite instability
microsatellite instability-high mCRC
microsatellite-instability-high advanced CRC
middel-heupomtrekverhouding
middelomtrek
middelomvang
middle-aged and older adults
midgut NETs
migraine
migratie naar hersenparenchym
MILD trial
MILES-3
MILES-4
million women study
MILO ENGOT-ov11 study
MILS
MINDACT
mindfulness
mindfulness-based cognitive therapy
mini-mental state examination
minimal residual disease
minimally invasive robotic surgery
minimally invasive versus open radical hysterectomy
minimally invasive versus open surgery
mipsagargin
MIPSS70
miR-126
miR-190b
miR-34
miR-345
miR-506
mirdametinib (PD-0325901)
miRNA
miRNAs
MIRO trial
MIRO-studie
mismatch repair deficient small bowel adenocarcinoma
mismatch repair status
Mitchell
MITCI-studie
MITO-8 studie
MITO-9 study
mitomycin C
mitosesnelheid
mitotische activiteitsindex
mitoxantrone
MK-2206
MK-3475
MK-4166 with or without pembrolizumab
MK-6482
MLBO
MM
MM and AL amyloidosis
MM-302
mMCC
MMR
MMR-D noncolorectal cancers
MMR-deficiency
MMR-deficiëntie
MMSE
mNPC
mNSCLC
mNSCLC in patients aged 80 years and over
mNSCLCwith PD-L1 tumor proportion score ≥ 50%
MNTX
mode of detection
mode of progression
model for predicting acute complications after surgery for breast cancer
moderately hypofractionated helical IMRT
moderately hypofractionated IMRT
modern chemotherapy
mogamulizumab
Mohs surgery versus wide margin excision
moleculaire subtypen
moleculaire tumormarkers
molecular classification
molecular markers of prognosis
molecular markers of recurrence
molecular pahtological subtypes and pathways
molecular profiling
molecular profiling for assessment of distant metastasis risk
molecular recurrence
molecular relapse detection
molecular risk stratification
molecular subtype
molecular subtypes
molecular subtypes of breast cancer
Molina
MONALEESA-2 studie
MONALEESA-3 overall survival analysis
MONALEESA-7 studie
MONALEESA-7 trial
MONARCH 1
MONARCH 1-studie
MONARCH 2 study
MONARCH 2-studie
MONARCH 3-studie
monarchE study
monarcHER trial
mondholte squameus celcarcinoom
mondholtecarcinoom
mondhygiëne
mondkanker
monoclonal antibody combined with induction chemotherapy
monoklonale B-cel lymfocytose
montelukast and rupatadine premedication
Moore-criteria
MOR202
morcellatie
mortaliteit
mortaliteit colorectaalcarcinoom
mortaliteit na kankerdiagnose
mortality
mortality after breast cancer
mortality and chronic health conditions
mortality as function of age
mortality due to cancer treatment delay
mortality from unrelated causes
mortality prediction by Oncotype DX
mortality risk
mortality trends
mortalteit
MOSAIC
MOSAIC trial post hoc analysis
moxetumomab pasudotox
mPCa
mPDAC
MplBC
MPM
MPN
MPNs
MPNs treated during pregnancy
MPR
mRCC
mRCC histologic varants
MRD-status
MRD-stratified treatment
mRECIST objecte response
MRI
MRI background parenchymal enhancement
MRI of ultrasonography for prostate concer screening
MRI plus targeted biopsy versus systematic biopsy alone
MRI staging of breast camcer
MRI-FIRST study
MRI-guided biopsy to verify pCR
MRI-screening
MRI-screening mammacarcinoom
MRI-targeted versus systematic versus combined biopsy
MS2010 study
MSC
mSCLC
MSE
MSG-carcinomen
MSI
MSI-CRC
MSI-H dMMR mCRC
MSI-H mCRPC
MSLCs
MSLT-II studie
mss CRC
MT-GCT
MTC
mtDNA
MTH1-remmers
MTL-CEBPA
mTNBC
mTOR-remmer
mTOR-remmers
mUC
mUC and other genitourinary tumors
mUC in patients with renal insufficiency or mixed variant histology
MUC16 mutations
mucosaal melanoom
mucosalaesies
mucositis
mucositispijn
mulitpel myeloom
Müllerian carcinoom
multi-antigen targeted T cells
multi-cancer detection and localization
multi-gen panel testing HBOC
multidisciplinary salvage treatment
multidrugresistentie
Multiethnic Cohort
multigene testing for all patients
multikinase inhibitors
multimodal therapy
multimodality management
multinational post registration study of nivolumab
multipel myeloom
multipel myeloom. KTd
multipele endocriene neoplasie
multiple brain metastases
multiple foci of microinvasion
multiple myeloma
multiple myeloma refractory to CD38 MoABs
multiple myeloma survival
multiple primary melanoma incidence
multiple sclerosis
MULTOMAB study
MURANO study
MURANO study 4-year results
MURANO-studie
muscle mass
muscle radiodensity
muscle-invasive bladder cancer
musculoskeletal burden
mutatiescreening
mutatievolgorde
mutation burden
mutation clearance
mutation profiling
mutation status and prognosis
mutation-enhanced prognostic system
mutational profile
mutational signature in colorectal cancer
mutations in cancer-associated genes
mutations in cancer-related genes
mutations in homologous recombination-related genes
mutp53 proteins
muziektherapie
MVAC
MVI
MVPA
MYC
MYC deregulated cancers
MYC rearrangement and translocation partner
Myc-remming
MYCN
mycobacterial infections
mycosis fungoides
myelodysplasie
myelodysplastic syndrome
myelodysplastic syndromes refractory to hypomethylating agents
myelodysplastisch syndroom
myelodysplastisch syndroom myeloproliferatieve neoplasmen
myelodysplastische syndromen
myelofibrose
myelofibrosis
myeloid malignancies
myeloïde neoplasie
myeloma
Myeloma X trial
Myeloma XI study
myeloom
myelopreservation with trilaciclib
myeloproliferatieve neoplasmen
MYL-14010
myocarditis
myomectomie
MyPathway study
MyPathway-studie
MYSTIC study
myxoid liposarcoma
MZL
n-3 fatty acids
N-cadherine
N1087-studie
N3 stage IIIB NSCLC in elderly patients
NA-PHER2 studie
Naakte molrat
nab-paclitaxel
nab-paclitaxel plus gemcitabine
nab-paclitaxel plus gemcitabine plus cisplatin
nab-paclitaxel versus paclitaxel
nabiximols oromucosal spray
NABON Breast Cancer Audit
NAC
nachtarbeid
NACT
NACT and IDS with or without HIPEC
NADIM study
nadofaragene firadenovec
naevi
NALA study
NALA trial
nanoparticles
nanotechnologie
NAPOLI-1 study
NAS
nasofarynxcarcinoom
nasopharyngeal cancer
nasopharyngeal carcinoma
National Breast and Cervical Cancer Early Detection Program
National Cancer Data Base
National Cancer Database analysis
National Institute for Health and Care Excellence
National Lung Cancer Screening Trial secondary analysis
natriumthiosulfaat
natural history and prognostic factors
natural killer
natural killer T-cel lymfoom
NAVIGATOR trial
NBTXR3
NC-6004
NCCN-richtlijnen
NCDB analysis of immunotherapy in resected stage III melanoma
NCGA
NCGC
NCI 8628
NCI-CONNECT
NCI-Maryland Case Control Study
NCI-MATCH study
NCI-MATCH subprotocol EAY131-Y
NCI-MATCH trial
NCI-Match Trial E131-Y
NCI-MATCH trial subprotocol H
NCI9673
NCIC CTG MA.27-studie
NCM
NCSLC
NCTN study S1001
NDMM
NDMM in transplant-ineligible patients
near real-time intraoperative brain tumor diagnosis
NEC study
NECC
necitumumab
nectin-4-positive solid tumors
negative colonoscopy
negative for intraepithelial lesions or maligancy
negative thyroid biopsy
NEJ009 study
nelarabine
nelfinavir with concurrent chemoradiotherapy
NELM
NELSON study
NELSON-studie
NEMO
NENs
neoadjuvant and adjuvant chemotherapy
neoadjuvant and adjuvant pembrolizumab
neoadjuvant anti-HER2 therapy for HER2-positive breast cancer
neoadjuvant aspirine
neoadjuvant atezolizumab
neoadjuvant atzolizumab plus chemotherapy
neoadjuvant bevacizumab
neoadjuvant CAPOX plus radiotherapy
neoadjuvant carboplatin plus docetaxel
neoadjuvant carboplatin with or without anthracycline
neoadjuvant chemoradiation
neoadjuvant chemoradiotherapy
neoadjuvant chemotherapy
neoadjuvant chemotherapy for breast cancer
neoadjuvant chemotherapy for early breast cancer
neoadjuvant chemotherapy plus nivolumab
neoadjuvant CRT
neoadjuvant CRT plus atezolizumab
neoadjuvant CRT with UGT1A1 status guided irinotecan dose
neoadjuvant dual checkpoint blockade
neoadjuvant durvalumab
neoadjuvant endocrine therapy
neoadjuvant endocrine versus chemotherapy
neoadjuvant erlotinib
neoadjuvant FOLFIRINOX
neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel
neoadjuvant gemcitabine plus S-1
neoadjuvant ICI
neoadjuvant immune checkpoint blockade
neoadjuvant immunotherapy
neoadjuvant lapatinib plus trastuzumab without chemotherapy
neoadjuvant larotrectinib
neoadjuvant mFOLFIRINOX and postoperative gemcitabine
neoadjuvant nab-paclitaxel
neoadjuvant nivolumab
neoadjuvant nivolumab plus ipilimumab
neoadjuvant nivolumab with or without ipilimumab
neoadjuvant pembrolizumab
neoadjuvant pertuzumab
neoadjuvant plus adjuvant erlotinib
neoadjuvant radiotherapy
neoadjuvant ribociclib-letrozole versus chemotherapy
neoadjuvant SABRT
neoadjuvant sintilimab
neoadjuvant T-DM1 plus lapatinib plus paclitaxel
neoadjuvant talazoparib
neoadjuvant TCHP
neoadjuvant therapy
neoadjuvant trastuzumab emtansine plus pertuzumab
neoadjuvant trastuzumab plus pertuzumab
neoadjuvant treatment
neoadjuvant zoledronic acid
neoadjuvant-treated breast cancer
neoadjuvante chemotherapie
neoadjuvante CRT
neoadjvuant systemic therapy
NeoALTTO
NeoCombi study
neonatal inflammatory markers
neonatal phototherapy
NeoPAL study
NeoPalAna
neoplasm detection in upper gastrintestinal tract
neoplasm risk
neopterine
NeoSTOP study
NEOZOTAC trial
nephrectomy
nephrotoxicity
neratinib
neratinib for HER2-positive breast cancer
nercelcarcinoom
NET
NET liver metastases
NETs
network meta-analysis of first-line treatments
network meta-analysis of regimens
neurale invasie
neuro-endocrien carcinoom
neuro-endocriene neoplasmen
neuro-endocriene tumoren
neuroblastoma
neuroblastoom
neurocognitie
neurocognition
neurocognitive function
neurocognitive problems
neurodegenerative outcomes
neuroendocrine prostate cancer
neuroeondocriene tumoren
neurofibromatose
neurofibromatose 1
neurofibromatosis type 1
neurofibromatosis type 1-related plexiform neurofibromas
neurologic disorders
neuropathie
neuropsychiatric functioning
neuropsychological outcomes
neutrofiel lymfocyt-ratio
neutrofiel-lymfocyt ratio
neutropenie
neutrophil to lymphocyte ratio
neutrophilia
never-smoker lung adenocarcinoma patients
New EPOC trial
new treatment options
newly diagnosed AML with IDH1-mutation in elderly patients
newly diagnosed APL
newly diagnosed cancer patients
newly diagnosed CML
newly diagnosed DLBCL
newly diagnosed early NK T cell lymphoma
newly diagnosed endometrial cancer
newly diagnosed glioblastoma
newly diagnosed low-burden metastatic prostate cancer
newly diagnosed multipel myeloma
newly diagnosed multiple myeloma
newly diagnosed multiple myeloma in transplant-ineligible patients
newly diagnosed or relapsed multiple myeloma
newly diagnosed stage IV squamous cell lung cancer
newly diagnosed T-ALL
newly diagnosed transplant-ineligible multiple myeloma
newly-diagnosed multiple myeloma
next-generation BRAF inhibitor PLX8394
next-generation flow cytometry for assessing measurable residual disease
next-generation sequencing
next-generation sequencing detected MET amplification
next-generation sequencing of ctDNA
NF1
NF1 mutations
NF1-related PNs
NF106 trial
NF2
NFκB
NGS
NHANES III analysis
nHL
NHL in AYAs
NHL subtypes in Sweden 2000-2016
NHL-001 study
NHS
NIBIT-MESO-1 studie
nice-or-naughty theorie
NICHE study
nicotine
niercarcinoom
niercelcarcinoom
niercelkanker
nierfunctie
niet-cervicale anogenitale maligniteit
niet-chirurgische behandeling
niet-invasief prenataal testen
niet-kelincellig longcarcinoom
niet-kleincellg longcarcinoom
niet-kleincellig longcarcinoom
niet-kleincellige longkanker
niet-melanoom huidkanker
niet-seminomateus testiscarcinoom
niet-squameus niet-kleincellig longcarcinoom
nieuw logo
Nieuw-Zeeland
NIFTP
night shift work
NIH-AARP
NIH-AARP cohort
NIH-AARP Diet and Health study
NIH-AARP Diet and Health Study prospective cohort
NIH-AARP Diet and Health Study; alcohol consumption
Nijmegen breakage syndrome
NILM
NiloPeg
nilotinib
nimotuzumab
nimotuzumab plus concurrent CRT
nintedanib
nipple-sparing mastectomy
NIPPON DATA 80
niraparib
niraparib after response to chemotherapy
niraparib maintenance
niraparib plus pembrolizumab
nitraat
nitriet
NIVAHL trial
nivolumab
nivolumab and AVD
nivolumab for advanced cancer
nivolumab for metastatic renal cell carcinoma
nivolumab for NSCLC
nivolumab plus gemcitabine and cisplatin
nivolumab plus ipilimumab
nivolumab plus ipilimumab and radiotherapy
nivolumab plus ipilimumab for NSCLC with brain metastases
nivolumab plus ipilimumab versus sunitinib
nivolumab plus ipilimumab with or without local therapy
nivolumab plus SBRT
nivolumab versus bevacizumab
nivolumab versus nivolumab plus ipilimumab
NIVOREN study
NK
NLCS
NLPHL
NLR
NLR as prognostic factor
NMA of treatment options
nmCRPC
NMIBC
nmPrCa
NMR
NMSC
NMSC-ASE
NMSIs
NNAL
no evidence of increased breast cancer risk
NO16968
NO2
NOA-07 studie
NOA-08 study
NOCCA study
nodal PTCL
node-positive breast cancer
node-positive HR-positive HER2-negative breast cancer
node-positive melanoma
node-positive vulvar cancer
node-postive HR+ HER2-breast cancer with RS≤25
nodulair lymfocyt-predominant Hodgkin lymfoom
nodular desmoplastic medulloblastoma in young children
NOM
nomogram for predicting mortality
nomogram to estimate individualized overall survival
Non Core Binding Factor AML
non-alcoholic fatty liver disease
non-engineered multi-antigen specific T cells
non-germinal center B-cell DLBCL
non-germinal center B-cell like diffuus grootcellig B-cel lymfoom
non-Hodgkin lymfoom
non-Hodgkin lymphoma
non-inferioriteits fase 3-studie AXEPT
non-melanoma skin cancer
non-metastatic castration-resistant prostate cancer
non-muscle-invasive bladder cancer
non-relapse mortaliteit
non-RMS soft tissue sarcoma in patients younger than 30 years
non-seminoom testikelkanker
non-small cell lung cancer
non-small cell lung cancer brain metastases
non-small cell lung cancer surgery
non-small cell lung cancer with MET exon 14 skipping mutations
non-specific symptoms and signs of cancer
non-squamous metastatic non-small cell lung cancer
non-squamous non-small cell lung cancer
non-V600 BRAF mutations
nonadherence
nonadherence to cancer screening
nonaspirin NSAIDs
noncancer mortality
noncolorectal dMMR MSI-H cancers
noncutaneous and cutaneous cancer risk
nonelderly adult cancer survivors
nongerminomatous malignant germ cell tumors
nonhereditary breast cancer
noninferiority phase 3 study HYPO-RT-PC
noninvasive prediction of occult peritoneal metastasis
nonmelanoma skin cancer
nonmetastatic breast cancer
nonmetastatic NPC
nonmetastatic prostate cancer
nonmetastatic retroperitoneal sarcoma
nonmetastic castration-resistant prostate cancer
nonoropharyngeal squamous cell carcinoma
nonpancreatic neuroendocrine tumors
nonsquamous NSCLC
nonverbale communicatie
Noorwegen
NOP10
NOPHO ALL2008 protocol
NOPHO ALL2008 study
NORCCAP-studie
Nordic BRCA2 mutation carriers
Nordic Lymphoma Group
NORDIC9 study
not previously treated mNSCLC
not transplant-eligilbe MM
notifying GPs regarding nonadherence to FIT screening
NOx
NPC
NPM1-gemuteerde AML
NPM1-mutated AML
NRAS-mutatie
NRAS-mutaties
NRF2 expression
NRG Oncology CC001 trial
NRG Oncology RTOG 0617 study
NRG Oncology RTOG 1203
NRG Oncology RTOG studie 0621
NRG-GY003
NSABP B-28 studie
NSABP B-31 study
NSABP B-40
NSABP B-41 neoadjuvant trial
NSABP B-42
NSABP B-42 study
NSABP FB-10 trial
NSAID
NSAID use
NSAID-gebruik
NSAIDs
NSCLC
NSCLC after EGFR TKI
NSCLC after PD-1 PD-L1 blockade
NSCLC brain metastases
NSCLC brain metastasis
NSCLC in performance status 2 patients
NSCLC in postmenopausal women
NSCLC progressing on various EGFR TKIs
NSCLC refractory to second-generation ALK inhibitor
NSCLC with ALK or ROS1-rearrangement
NSCLC with brain metastases
NSCLC with high PD-L1 expression
NSCLC with uncommon EGFR mutations
NSCLC; linifanib
NSGCT
NSM
nsq NSCLC
nsq-NSCLC
nsqNSCLC
NTD-Haplo versus SUCBT
NTP
nucleaire installaties
nuclear ZEB2 expression
number of doses
Nurses' Health Study
Nurses’ Health Studies
Nurses’ Health Study
Nurses’ Health Study I and II
Nurses’ Health Study II
nursing home residents
nut consumption
nutrient intake
NutriNet-Santé cohort
NutriNet-Santé prospective cohort
NutriNet-Santé studie
NutriNet-Santé study
nutritional status
NVALT19 trial
NWAS
NWTS-5
OA-MCL
OAC
OAC for AF
OAK
OAK and POPLAR trials
OAK-studie
obesitas
obesitasparadox
obesity
obesity paradox
obesity-related cancer trends
obinutuzumab
obinutuzumab plus DHAP
obinutuzumab plus lenalidomide
observation versus SABR
Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk
obstetric and maternal outcomes
obstetric outcomes
OCC
OCCC
occult breast cancer
occulte kanker
occupational variation
OCSCC
ocular toxicity of bortezomib
ODM-201
odontoom
ODXRS
oedeem
oesofagaal squameus celcarcinoom
oesofagastrische tumoren
oesofagectomie
oesofagogastrisch adenocarcinoom
oesofagus squameus celcarcinoom
oesofagusadenocarcinoom
oesofaguscarcinoom
oesofaguskanker
oesophageal cancer
oesophageal squmous cell carcinoma
oestradiol
oestrogeengebruik
oestrogeenreceptor
oestrogeensuppressie
ofatumumab
offspring donors versus HLA-matched siblings
offspring of survivors of childhood or adolescent CNS tumors
ofranergene obadenovec
OGC
OHERA study
Okayama Lung Cancer Study Group Trial 1404
olanzapine
olaparib
olaparib maintenance
olaparib monotherapy
olaparib plus bevacizumab maintenance
olaparib plus cetuximab and IMRT
olaparib plus durvalumab
olaparib plus temozolomide combination
olaratumab
older adults with blood cancer
older adults with cancer
older breast cancer patients with high recurrence scores
older cancer patients
olfactorisch neuroblastoom
oligometastase
oligometastatic cancer
oligometastatic cancers
oligometastatic non-small cell lung cancer
oligometastatic NSCLC
oligometastatic oligoprogressive NSCLC
oligometastatic prostate cancer
OLIVIA
olmutinib
OlympiAD-studie
OLYMPUS study
OM-CRC
omacetaxine mepesuccinate
omega 3-vetzuren
OMEGA offspring cohort
omission of dexamethasone
on-target adverse events
ONC201
once weekly selinexor-bortezomib-dexamethasone
oncolytisch adenovirus
oncolytische virustherapie
oncoplastische mammoplastie
Oncoscience
Oncotype
Oncotype DX
Oncotype DX DCIS-score
ondergewicht
onderhoudstherapie
ondervoeding
onderzoeksfraude
one week off
ONJ
online predictor of short-term postoperative outcomes
online preview AACR Annual Meeting
ONT-380
ontstaan colorectaalkanker
ontwikkeling resistentie
oogmelanoom
Oost-Afrika
OPAS-1 study
OPC
open resectie
open versus minimally invasive surgery
operable oral and oropharyngeal cT1-T2N0 cancer
operable TNBC
opioid use
opioid use among older cancer survivors
opioid use and toxicity among cancer survivors
opioid-associated mortality in cancer survivors versus general population
opleidingsniveau
OPN
opportuniby costs of receiving palliative chemotherapy
OPSCC
opsoclonus-myoclonus ataxie syndroom
OPTIMA Prelim
optimal adjuvant trearment time
optimal neoadjuvant sequence of anthracyclines and taxanes
optimal RT regime
optimal RT strategy after breast-conserving surgery
optimal sequence of enzalutamide and abiraterone acetate plus prednisone
optimal timing of chemoradiotherap
OPTIMISMM study
optimizing chemotherapy
optimizing patient selection for cytoreductive nephrectomy
OPTION-studie
Opto-RTKs
oraal carcinoom
oraal oncogeen HPV
oral androgen signaling inhiibitos
oral arsenic trioxide
oral azacitidine maintenance
oral cancer
oral cavity or oropharyngeal squamous cell carcinoma
oral cavity squamous cell carcinoma
oral contraceptive use
oral endocrine therapy
oral health
oral hydration after cisplatin
oral mucositis after chemoradiotherapy for OCC OPCC
oral mucositis with high-dose chemotherapy and transplanation
oral S-1
orale anticonceptiva
orale contraceptiva
ORALEV study
ORATOR study
ORCA-010
ORCHARRD
orgaantransplantatie
Organ transplant recipients
organ-sparing transanal endoscopic microsurgery
organic food consumption
organische oplosmiddelen
organoids from colorectal peritoneal metastases
orgnnoïdencultures
ORIENT-1 study
ORIOLE trial
orofaryngeaal squameus celcarcinoom
orofarynx squameus celcarcinoom
orofarynxcarcinoom
oropharyngeal cancer
oropharyngeal carcinoma in older patients
oropharyngeal HPV infections
oropharyngeal squamous cell carcinoma
ORR and six months PFS as surrogate endpoints for OS
orthopedische oncologie
OS
OS2006 Sarcome-09 study
OSCC
osimertinib
osimertinib 160 mg
osimertinib for advanced T790M-positive and -negative NSCLC
osimertinib for NSCLC
osimertinib plus navitoclax
osimertinib plus savolitinib
OSJ
Oslo 1-studie
OSLO-COMET study
osteonecrose van de kaak
osteopenie
osteopontin
osteoporosis
osteosarcoma
osteosarcoom
ototoxiciteit van chemotherapie
OTX015
outcomes
outcomes after surgery
outcomes by prior treatment at first relapse
outcomes in cancer patients
outcomes of CRT
outcomes of primary endocrine therapy
outcomes of rechallenge after high-grade heaptitis
outcomes of risk-reducing total gastrectomy
outcomes of surgery
outcomes of various RIC-NMAC conditioning regimes
outcomes without locoregional treatment
OV21 PETROC
ovarian cancer
ovarian cancer and borderline tumors
ovarian cancer in women aged 65 years and older
ovarian cancer risk
ovarian cancer survival
ovarian cancer survivors
ovarian function
ovarian function suppression
ovarian or endometrial cancer
ovarian removal at or after benign hysterectomy
ovarian stimulation
ovarian tumors
ovariëctomie
ovariumcacrinoom
ovariumcarcinoom
ovariumfunctie
ovariumfunctie-suppressie
ovariumfunctiesuppressie
ovariumkanker
ovariumtumoren
ovariumvolume
OVC
overall and specific cancer risks
overall mortality in men versus women
overall survival
overall survival trend from 2000 to 2019
overall survival-analyse van fase 3-studie ARCHER 1050
overdiagnose
overdiagnosis
overgewicht
overhospitalisatie overlevers
overlevers jeugdkanker
overlevers kinderkanker
overleving
overleving borstkanker
overleving CRC
overleving in Europa
overleving melanoom
overleving oudere patiënten
overweight
oviductcarcinoom
oxaliplatin
oxaliplatin hepatic artery infusion
oxaliplatin-based adjuvant chemotherapy
oxaliplatine
oxybutynin
p16 Ki-67 dual stain and HPV16 18 genotyping
p53
PABC
PACE-B study
PACE-studie
pachymeningeal seeding
PACIFIC study
PACIFIC study post-hoc analysis
PACIFIC trial update
PACIFIC-studie
paclitaxel
paclitaxel for breast cancer
paclitaxel- and oxaliplatin-induced peripheral neuropathy
PACMEL trial
PACT trial
PACT-15 studie
PACT-19 study
PADT
pain and pain interference
pain in older survivors
painful spinal metastases
Painyanitikul
PAKT trial
PALB2 germline mutations
PALB2-mutatie
PALB2-mutaties
palbociclib
palbociclib combination therapy for advanced or metastatic breast cancer
palliatie
palliatieve radiotherapie
PALOMA-1 TRIO-18
PALOMA-2 analyse
PALOMA-3
PALOMA-3 analysis
PALOMA-3 study
PAM50 signature
PAMELA
PAMELA-studie
pamiparib plus tislelizumab
pan-cancer noninvasive detection of MSI and high TMB
pan-RAF remmers
PANACEA study
pancreas
pancreas cancer
pancreas ductaal adenocarcinoom
pancreas-adenocarcinoom
pancreas-ductaaladenocarcinoom
pancreas-MCNs
pancreasadenocarcinoom
pancreascarcinoom
pancreaskanker
pancreatectomie
pancreatic adenocarcinoma
pancreatic cancer
pancreatic cancer risk
pancreatic cystic neoplasms
pancreatic ductal adenocarcinoma
pancreatic fistula
pancreatic head adenocarcinoma
pancreatic NETs
pancreatic neuroendocrine tumors
pancreatic-colorectal-stomach cancer
pancreaticoduodenectomie
pancreaticoduodenectomy
pancreaticoduodenectomy for pancreatic cancer
PANFIRE
PANFIRE-2 study
panitumumab
panitumumab versus cetuximab after bevacizumab
panobinostat
PANORAMA 3 study
PANTHER trial
Panther trial long-term HRQOL
PANVAC
PAOLA-1 study
PAPAGEMO trial
papillair craniofaryngioom
papillair metastatisch niercelcarcinoom
papillair schildkliercarcinoom
papillary neoplasms of the breast
papillary thyroid carcinoma aggressive variants
paraganglioma
paraneoplastisch neurologisch syndroom
parasagittal meningioma
parity
Parkinson
PARP inhibitor treatment
PARP-remmer
PARP1-expressie
partial hepatectomy versus TACE
partial prostate treatment
partial versus whole breast irradiation
particle radiation therapy
particpating in randomized breast cancer study
PAs
passief roken
PASSION trial
PASSOS Heart studie
PATCH trial program
pathogenic germline variants
pathogenic variants in less familiar cancer susceptibily genes
pathogenic variants in RAD51C and RAD51D
pathologic fractures
pathologic stage II nonseminomatous ger cel tumors
pathological nipple discharge
pathologically node-negative neck
patient age and progression
patient and diagnostic intervals of sarcoma survivors
patient factors and ratio of basal cell to cutaneous squamous cell carcinoma
patient factors associated with prognosis
patient mortality after surgery on surgeon’s birthday
patient reported outcome
patient reported outcomes
patient reported symptoms
patient volume of oncologist
patient- and clinican-reported
patient- and clinician-reported symptoms during standard RT or IMRT
patient- and hospital-level risk factors
patient-collected versus clinician-collected samples
patiënt-gerapporteerde uitkomsten
patient-reported outcomes
patiëntnavigatie
patients aged 40 years or younger
patients with 4-15 brain metastases
patients with cancer and acute deep venous thrombosis
patients with COVID-19 and solid tumors
patients younger than 50 years
patterns and survival
patterns of recurrence
patterns of relapse
patterns of relapse after neoadjuvant chemotherapy in clinical practice
patterns of treatment and outcome in The Netherlands
PAVO study
pazopanib
pazopanib plus cetuximab
pazopanib versus doxorubicin
pazopanib with or without gemcitabine
PBC
PBL
PBSO
PBT
PBT versus IMRT
PC
PCa diagnosis
PCD
PCI
PCLO
PCNSL
PCOS
pCR
pCR after NACT
pCR and outcomes by intrinsic subtypes of breast cancer
pCR to NACT
pCR to pertuzumab and trastuzumab
PCS with or without HIPEC
PCSNL
PD-(L)1 blockade for NSCLC
PD-(L)1 inhibitors
PD-(L)1-blockade
PD-1
PD-1 Ab
PD-1 and PD-L1 checkpoint inhibitors
PD-1 and PD-L1 inhibitos
PD-1 blockade
PD-1 blockade for melanoma
PD-1 inhibitor
PD-1 inhibitors for mNSCLC
PD-1 PD-L1 inhibitors
PD-1 PD-L1 targeting
PD-1-inhibitor therapy
PD-L1
PD-L1 expression
PD-L1 expression as predictive biomarker
PD-L1 negative NSCLC
PD-L1-inhibitor LY3300054
PD-L1-positive advanced NSCLC
PD-L1-positive mTNBC
PD1 inhitiors for NSCLC
PDAC
PDGFRA D842V-mutated GIST
PDS
PDT
PEAK study
pediatric acute leukemia
pediatric ALL
pediatric AML
pediatric and youg adult cancer surivors
pediatric BRAF V600E-mutated glioma
pediatric brain tumor survivors
pediatric cerebral microbleeds
pediatric CT-related radiation exposure
pediatric ependymoma
pediatric germ cell tumors
pediatric hepatoblastoma
pediatric locally advanced TRK fusion sarcomas
pediatric low-grade glioma
pediatric medulloblastoma
pediatric neuro-oncology
pediatric neuroblastoma
pediatric or adolescent NHL
pediatric Ph+ ALL
pediatric Ph+ CML-CP
pediatric posterior fossa tumors
pediatric R R ALL
pediatric recurrent ependymoma
pediatric recurrent or refractory CNS tumors
pediatric relapsing high-risk ALL
pediatric spinal cord low-grade glioma
pediatric thyroid cancer incidence and mortality trends
pediatrisch ALL
pediatrisch AML
pediatrisch ependymoom
pediatrisch sarcoom
pediatrische AML
pediatrische CNS-tumoren
pediatrische hersentumoren
pediatrische leukemie
pediatrische NETs
pediatrische patiënt-gerapporteerde uitkomsten
pediatrische stamceltransplantatie
PEG
PEG-IFN
PEGASUS
PEGASUS-D trial
pegfilgastrim
pegfilgrastim-profylaxe
pegilodecakin
peginterferon alpha-2b
pegteograstim
pelareorep
pelvic fractures and changes in bone mineral density
pelvic radiotherapy
pelvic RT versus IMRT
pembolizumab
pembolizumab with bevacizumab and oral metronomic cyclophosphamide
PEMBRO-RT study
pembrolizmab
pembrolizumab
pembrolizumab activity
pembrolizumab after concurrent CRT
pembrolizumab after locally ablative therapy
pembrolizumab and concurrent CRT
pembrolizumab for advanced melanoma
pembrolizumab for advanced NSCLC
pembrolizumab for advanced prostate adenocarcinoma
pembrolizumab for previously treated mTNBC
pembrolizumab for previously treated PD-L1 positive advanced NSCLC
pembrolizumab for previously untreated
pembrolizumab for solid tumors
pembrolizumab monotherapy for aNSCLC
pembrolizumab plus axitinib
pembrolizumab plus axitinib versus sunitinib
pembrolizumab plus bevacizumab
pembrolizumab plus CRT
pembrolizumab plus enzalutamide
pembrolizumab plus GX-188E DNA vaccine
pembrolizumab plus ipilimumab
pembrolizumab plus nab-paclitaxel salvage
pembrolizumab plus NACT
pembrolizumab plus RT after induction chemotherapy
pembrolizumab plus trastuzumab
pembrolizumab versus best supportive care for advanced HCC
pembrolizumab versus chemotherapy
pembrolizumab versus ipilimumab
pembrolizumab with or without RT
pembrolizumab-etoposide-platinum
pemetrexed and platinum
pemetrexed for lung cancer
pemetrexed plus carboplatin
pemetrexed plus cisplatine
pemigatinib
penta-refractory MM
peptide receptor radionuclide therapy
percent ctDNA
percentage dense area
perception of cancer risk
percutaneous ablation
percutaneous cryoablation
percutaneous IRE
PerELISA neoadjuvant study
PERFECT trial
perfluarinated alkylated substances in serum
perifeer T-cel lymfoom
perifere neuropathie
perinatal and postnatal exposures
perinatal exposures
perinatal outcomes
periodontale ziekte
perioperative cell-free DNA dynamics
perioperative COX2 and β-adrenergic blockade
perioperative dynamic changes in ctDNA
perioperative FLOT versus ECF ECX
perioperative radiotherapy
peripheral neuropathy
peripheral T-cell lymphoma
peripheral T-cell lymphoma in elderly patients
perirectal hydrogel spacer
peritoneal mesothelioma
peritoneal metastases from gastric cancer
peritoneale carcinomatose index
peritoneale metastasen
PERSEPHONE trial
PERSIST-1
PERSIST-2 studie
PERSIST-5 trial
persistence of F. nucleatum
persistent acromegaly
persistent febrile neutropenia
persistent postchemotherapy alopecia
persistent radiation-induced alopecia in cancer patients
persistente pijn
personalised versus standard dosimetry
personalized ctDNA as predictive biomarker
personalized ctDNA profiling
personalized neoantigen vaccine monotherapy
PERTAIN study
pertuzumab
pertuzumab plus trastuzumab
peru
PERUSE study
pesticide exposure
PET
PET CT
PET CT for predicting PD-L1 expression
PET-CT
PET-CT staged localized follicular lymphoma
PET-guided omission of radiotherapy
PET-guided risk adapted treatment
PET-guided therapy
PET-guided treatment
PETAL-studie
PETHEMA GEM2012 study
PETra trial
peulvruchten
pevonedistat
pexidartinib
PF-05280014
PFAS in serum
PFS
PFT
PGC-1α
PGF
PGHD
PGT
Ph- ALL
Ph-ALL
Ph-like ALL
Ph-negative ALL in older patients
Ph-negative CD20-positive B-cell ALL
Ph-positive ALL in adults
Ph+ ALL
phase 1 oncology trials
phase 2 ACCRU study
phase 2 adaptively randomized I-SPY2 trial
phase 2 BENEFIT trial
phase 2 CONTROL trial
phase 2 GEMCAD 1402 study
phase 2 HORIZON trial
phase 2 PEANUT study interim results
phase 2 PETREMAC study
phase 2 study JULIET
phase 3 FIRE-3 study
phase 3 JAVELIN Gastric 100 study
phase 3 KEYNOTE-062 study
phase 3 monarchE study
phase 3 NEJ026 study
phase 3 study AML08
phase 3 study COMBI-AD
phase 3 study TRAIN-2
phase 3 study TRIBE 2
phase 3 trial RADAR
phase III IMpower131 study
phase III POLO trial
phase III SUCCESS-A trial
Phc
pheochrmocytoma
pheochromocytoma
PHEREXA-studie
Philadelphia chromosome-negative ALL
Philadelphia-negative B-cell ALL
PHILEMON-studie
PHL86 NCI#9322 study
phlebotomy with or without ropeginterferon α-2b
PHOEBE trial
PHOENIX study
photodynamic therapy
PHP-Mel
physical activity
physical activity during adolescence
physican workforce requirements
physicians’ perspectives
PI3K inhibitors
PI3K mTOR-remming
PI3K-signalering
PI3Kδ
PIB
PICN
pictilisib
pigmented skin lesion classification
pijnlijke botmetastasen
PIK3CA
PIK3CA-altered HNSCC
PIK3CA-mutated HR+ HER2- advanced breast cancer
PIK3CA-mutaties
pilaralisib
pilocarpine
pimasertib versus dacarbazine
pimecrolimus
pioglitazon
pituitary macroadenomas
pituitary metastasis
PIVOT-studie
pixatimod plus nivolumab
PL
placebo adverse events in cancer trials
PLACOL-studie
plaque radiotherapy for uveal melanoma
plasma exosomal miRNAs
plasma-based genotyping
plasma-biomarkers
plasmacarotenoïden
plasmaMATCH trial
platinum exposure
platinum-based chemotherapy
platinum-pemetrexed
platinum-refractory early failure oral cancer
platinum-refractory mUC
platinum-resistant high-grade serous ovarian cancer
platinum-resistant or platinum-refractory ovarian cancer
platinum-resistant ovarian cancer
platinum-resistente ovariumkanker
platinum-sensitive recurrent ovarian cancer
platinum-sensitive relapsed ovarian cancer in gBRCA1 2 mutated patients
PLATO study
plaveiselcelcarcinoom
PLCO cancer screening trial
PLCO trial
pleiomorf lobulair mammacarcinoom
pleister
pleural mesothelioma
pleurectomie
pleurectomy decortication
PLGA
PLGG
plinabulin vs pegfilgrastim
ploegendienst
PLP
PLR
PLRG Observational Study
PM
PMBCL
PMF
PMRT
PN
pnacreascarcinoom
pNET
PNET HR+5 trial
pneumonitis
PO-IMRT versus PPLN-IMRT
POD24
POEMS final analysis
Poland
POLARIS-02 trial
polatuzumab vedotin
POLE-mutaties
POLLUX and CASTOR studies
POLLUX-studie
POLO study
polo-like kinaseremmer
poly-G repeats
polycyclische aromatische koolwaterstoffen
polycystic ovary syndrome and breast cancer risk
polycystische nierziekte
polycythemia vera
polyfarmacie
polymerase theta
polymorfismen
polypectomie
polypharmacy
polypose
pom-dex
pomalidomide
pomalidomide-dexamethasone-daratumumab
ponatinib
pooled analysis
POP-RT study
population-based study of immunotherapy-related toxicities
population-based treatment patterns and survival
population-level survival
PORT
PORTEC-3
PORTEC-3 analysis
PORTOS
POSH-studie
positive initial margins
positive margins
post hoc analyse ASPIRE-studie
post hoc analyse FIRST-studie
post hoc analyse KEYNOTE-001 studie
Post hoc analysis PACIFIC study
post hoc exploratieve analyse RAISE-studie
post-hoc analyse PETACC-8 studie
post-hoc analyse REACH-studie
post-hoc analysis of CheckMate 227
post-induction ctDNA analysis
post-mastectomie radiotherapie
post-progression outcomes
post-transplant cyclophosphamide
post-transplantie lymfoproliferatieve ziekte
postdiagnosis BMI and weight change
postdiagnostic calcium intake
postdiagnostic metformin use
postembolization syndrome
postmastectomy radiotherapy
postmenopausal advanced HR-positive breast cancer
postmenopausal bleeding
postmenopausal breast cancer
postmenopausal breast cancer. oncogenic drivers of late distant recurrence
postmenopausal cancer
postmenopausal CRC risk
postmenopausal early-stage breast cancer
postmenopausal endometrial cancer screening
postmenopausal ER-positive DCIS
postmenopausal HER2-positive HR-positive MBC
postmenopausal HR+ HER2- metastatic breast cancer
postmenopausal women
postmenopauzaal mammacarcinoom
postmenopauzaal mammarcinoom
postmenopauzal HR+ HER2- breast cancer
postmenopauzale borstkanker
postmenopauzale hormoontherapie
postmenopauzale vrouwen
postoperatieve mortaliteit
postoperative [11C]-methionine accumulation
postoperative mortality
postoperative radiation field
postoperative radiation therapy
postoperative radiotherapy
postoperative seizures
postoperative SRS
postoperative surveillance
posttraumatische stressstoornis
POTENT trial
potential cost implications
potential years of life lost due to cancer
potentially modifiable risk factors
POUT trial
power morcellation
poziotinib
PPAR-gamma
pPCL
PPGL during pregnancy
PPIs
PR status
PR-status
PR1
PRACTICAL-studie
PrCa
PRCC
pre- and post-diagnosis smoking
pre-BCS MRI
pre-diagnosis dietary patterns and survival
pre-GKRS leucocyt ratios
pre-leukemisch
pre-operative MRI imaging
PrE0505 study
PRECIS study
precisie-oncologie
precisietherapie
precision medicine
PRECISION-studie
PRecur model
precursor stages of multiple myeloma
prediabetes
prediagnositc frailty
prediagnostic bile acid levels
prediagnostic immune cell profiles and breast cancer risk
prediagnostic signs and symptoms
prediagnostic telomere length
PREDICT
predicting 90-day mortality after concurrent chemoradiotherapy
predicting chemotherapy benefit
predicting outcomes of various interventions for DCIS
predicting pCR
predicting severe toxicity from chemotherapy for early-stage breast cancer in older patients
prediction for 2020
prediction model
prediction of AML risk in healthy individuals
prediction of early progression
prediction of invasive cervical cancer
prediction of MSI
prediction of outcome
prediction of outcomes of ibrutinib for CLL
prediction of progression
prediction of recurrence in early-stage LUAD
prediction of response to anti-PD-1 therapy
prediction of response to neoadjuvant chemotherapy plus bevacizumab
predictions for 2019
predictive role of frameshift mutations
predictive role of tumor infiltrate
predictive value of ctDNA
predictive value of ECOG performance status ≥ 2
predictive value of pretreatment circulating tumor DNA
predictive value of SNP-signature for recurrence
predictors of dacomitinib response
predictors of early relapse
predictors of outcome of HCT
predictors of recurrence
predictors of recurrence after laparoscopic radical hysterectomy
predictors of reponse to immune checkpoint inhibitors
predictors of response and survival
predictors of response to anti-PD-1 PD-L1 therapy
predictors of survival
predictors of uptake of CPM
preëclampsie
preemptive local ablative therapy to residual oligometastases
preexisting antibodies
preexisting pain
PREF ALL
pregabalin
pregnancy
pregnancy after cancer diagnosis
pregnancy duration
pregnancy outcomes
pregnancy-associated breast cancer
pregnancy-associated cancer
pregnancy-related risk factors
prehabilitatie
prehabilitation
preïmplantatie-genetische diagnose
premature menopauze
premenopausal breast cancer
premenopausal breast cancer risk
premenopausal HR-positive HER2-negative advanced breast cancer
premenopausal HR-positive HER2-negative metastatic breast cancer
prenatale blootstelling
prenatale carcinogenenblootstelling
PREOPANC study
preoperatieve chemotherapie
preoperatieve MRI
preoperatieve radiotherapie
preoperatieve radiotherapie voor rectumkanker
preoperative adverse event risk index for head and neck cancer surgery
preoperative anemia
preoperative CA19-9 and CEA
preoperative chemotherapy or radiotherapy
preoperative CRT
preoperative CRT with or without pazopanib
preoperative detection of KRAS G12D mutation in ctDNA
preoperative elevated tumor markers
preoperative embolization
preoperative letrozole
preoperative mFOLFOX6 plus cetuximab
preoperative MRI
preoperative nomogram predictive for early recurrence after pancreatectomy
preoperative oral antibiotics
preoperative PET CT
preoperative radiotherapy for retroperitoneal primary sarcoma
preoperative risk evaluation
Preoperative-Palbociclib studie
presalvage radiotherapy PSA level
prescription opioid use
presentation and characteristics
PRESSING panel mutations
preterm birth
preterm birth and risk of childhood cancer
pretreated advanced biliary tumors
pretreated ALL
pretreated STS
pretreatment vitamin D deficiency
PREVAIL-studie
prevalence and prognostic implications of accelerated aging
prevalence and risk factors
prevalence of altered body image
prevalence of clinical diagnosis of ADHD
prevalence of HBV
preventie
preventie cervixkanker
preventie mammacarcinoom
prevention of early menopause
prevention with polaprezinc
preventive drugs in the last year of life
previously diagnosed primary malignancies in Swedish breast cancer patients
previously treated advanced cervical cancer
previously treated advanced gastric cancer
previously treated advanced hepatocellular carcinoma
previously treated advanced KRAS-mutated NSCLC
previously treated advanced non-squamous NSCLC
previously treated advanced NSCLC
previously treated advanced urothelial carcinoma
previously treated aNSCLC
previously treated cholangiocarcinoma
previously treated MM
previously treated PD-L1 expressing advanced NSCLC
previously treated small-cell lung cancer
previously treated solid tumors in children and young adults
previously treated sqNSCLC
previously untreated AML
previously untreated high-risk AML
previously untreated locally recurrent or metastatic TNBC
previously untreated MPM
prijzen medicatie
PRIMA study
primair CNS-lymfoom
primair melanoom
primair urethracarcinoom
primaire borstkanker
primaire plasmacelleukemie
primary brain tumor patients
primary breast cancer treatment
primary care clinic appointment time
primary central nervous system DLBCL
primary central nervous system lymphoma
primary CNS lymphoma
primary cutaneous melanoma
primary debulking surgery
primary dural lymphoma
primary HPV testing with cytology versus cytology alone
primary liver cancer
primary liver resection for HCC
primary mediastinal large B-cell lymphoma
primary surgery
primary tumor location
primary tumor resection
primary tumor sidedness
primary versus acquired T790M mutatiion
PRIME study
PRINCIPAL study
PRO-CTCAE
PRO-IMPACT studie
PROACCT score
ProCAID study
PROCAS Study
PRODIGE 20-studie
PRODIGE 9 trial analysis
PRODRIGE18 study
PROFILE 1001 study
ProfiLER-studie
PROFILES registry
PROfoud Trial OS analysis
PROfound study
profylactic salpingo-oophorectomy
profylactische mastectomie
prognose
prognose luminal A
prognosis
prognosis of screen-detected versus interval breast cancers
prognostic and predictive relevance of CMSs
prognostic and predictive value of Immunoscore
prognostic biomarkers for salvage chemotherapy following nivolumab
prognostic case volume thresholds
prognostic factors
prognostic factors and outcomes after progression
prognostic impact of HR subtypes
prognostic implications
prognostic index
prognostic model
prognostic nomogram
prognostic parameters in lobular versus nonlobular disease
prognostic protein-based signature
prognostic relevance
prognostic relevance of 21-gene recurrence score
prognostic risk score
prognostic role in lung cancer
prognostic role of circulating cell-free DNA
prognostic role of hypoxia and angiogenesis
prognostic role of pre-diagnosis health-related quality of life
prognostic role of TILs
prognostic score
prognostic signature based on DNA repair genes
prognostic significance
prognostic significance of early detection of KRAS-mutation in cfDNA
prognostic significance of metastatic pattern
prognostic significance of microsatellites
prognostic significance of NLR
prognostic value of CTCs
prognostic value of depth of response
prognostic value of EndoPredict
prognostic value of HER2-status of CTCs
prognostic value of histopathological subtyping
prognostic value of MPS
prognostic value of teratoma in primary tumor and postchemotherapy lymph nodes
prognostic value of TILs
prognostication
prognosticators
prognostische biomarker
prognostische discordantie
prognostische test
prognostische tools mammacarcinoom
progress in cancer survival and incidence
progressievrije overleving
progressievrije overleving na 24 maanden
progression risk stratification
progressive and symptomatic medullary thyroid cancer
progressive glioblastoma
progressive mACC
progressive metastatic breast cancer
progressive MPM
projections until 2030
prolaris
prolonged infusion of low dose gemcitabine
prolonged-duration chemoprophylaxis of venous thromboembolism
PROLUNG study
PROMIS-studie
PROMISE-studie
promotie
PRONOPALL-studie
propanolol plus pembrolizumab
PROPHECY study
prophylactic chestwall irradiation
prophylactic contralateral breast irradiation
prophylactic cranial irradiation
prophylactic heparin in ambulatory patients with solid tumors
prophylactic intravitreal bevacizumab
proportion of patients receiving ultimately approved treatments
PROREPAIR-B study
PROs
PROs after BCT versus mastectomy with reconstruction
PROSELICA-studie
Prosigna
Prosigna risk of recurrence score
prospective genotyping
prospective study of association of lever function and CRC risk
prospective validation Gail Model
PROSPER study
PROSPER study final OS analysis
prostaatcarcinoom
prostaatcarcinoom. androgeendeprivatietherapie
prostaatkanke
prostaatkanker
prostaatkankermortaliteit
Prostaid
prostate cancer
prostate cancer aggressiveness
prostate cancer diagnosis
prostate cancer incidence and mortality
prostate cancer mortality
prostate cancer outcomes following solid-organ transplantation
prostate cancer prognosis
prostate cancer progression
prostate cancer risk
prostate cancer risk and mortality
prostate cancer treatment
prostate cancer treatments
prostate cancer; long-term follow up NRG RTOG 9413 study
prostate radiotherapy with adjuvant versus neoadjuvant androgen deprivation
prostate tumors from African American and European American men
prostate-only versus whole-pelvic RT
prostatectomie
proteasome inhibitor
proteasoomremmer
ProtecT
PROTECT-1 en -2 studies
PROTECT-studie
proton beam radiation therapy
proton beam radiotherapy
proton beam therapy
proton craniospinal irradiation
proton radiotherapy
proton therapy
proton versus photon radiotherapy
protonradiotherapie
protontherapie
PROUD-PV and CONTINUATION-PV studies
proximal colon serrated neoplasia
proximal versus distal detection
PRT
PRT and CIRT
PS
PSA
PSA bounce
PSA levels in men aged 55-60
PSA screening
PSA-based EFS as surrogate for OS
PSA-recidief
PSA-screening
PSAD
PSCCB
PSMA PET-CT versus conventional imaging
pSmad2
PSN
psoriasis
psoriasis and psoriatic arthritis
psychiatric disorders in cancer patients
psychiatric utilisation prior to cancer diagnosis
psycho-oncology
psychologic distress
psychological distress
pT1 node-negative TNBC
PTBP1
PTC
PTCL
pten
PTEN loss predicts poor prognosis
PTEN-verlies
PTGS2
PTH
PTSD
pubertal timing and breast cancer risk
pulmonaire metastasen
pulmonary adenocarcinoma
pulmonary embolism
pulmonary fibrosis
pulmonary large cell neuroendocrine carcinoma
purchase of antidepressants
PURE study
PURE-01 study
PUVA therapy
PV
PVRL
pyrotinib
pyrotinib plus capecitabine
Q-koorts
QNBC
QoL
QOL analysis
QOL and psychosocial well-being in young survivors
QOL in CARD study
QOLIXANE trial
QSkin-studie
QUADRA study
quadrivalent HPV vacinnation
quality of life
quality of life in survivors of adolescent and young adult cancer
quality of surgery
quality-adjusted time without symptoms of progression or toxicity
QuANTUM-R study
QUAZAR AML-001 Maintenance Trial
QUAZAR AML-001 trial
QuiRedex
quizartinib
R M ACC
R M head and neck cancer
R M HNC
R M HNSCC
R R AML
R R AML in patients not eligible for intensive therapy
R R AML MDS
R R B-ALL
R R B-NHL
R R cHL
R R CLL
R R DLBCL
R R FLT3-mutated AML
R R folliculair B-cell lymphoma
R R FTL3-mutated AML
R R high-risk CLL
R R HL
R R large B-cell lymphoma
R R LBCL
R R lymphoma
R R MCL
R R MF SS
R R MM
R R MZL
R R NHL
R R PCNSL
R R peripheral T-cell lymphoma
R R PMBCL
R R PTCL
r r-AML
R-cadherine
R-CHOP
R-CHOP 14 versus 21 studie
R-CHOP-14
R-M HNSCC
R2-CHOP
RAAS
race and risk of subsequent aggressive breast cancer
race and survival
race ethnicity-associated differences in stage at diagnosis and survival among leading cancer types
race-based differences in survival
race-dependent differences in risk of MGUS progression
race-specific differences
radcial cystectomy
RADIANT-2
RADIANT-4
radiation and androgen deprivation for Pca
radiation and chemotherapy
radiation doses to organs at risk
radiation for localized prostate cancer
radiation pneumonitis
radiation therapy for cancer
radiation therapy plus ICI therapy
radiation to hypothalamus and pituitary
radiation-associated intracranial malignancy
radiation-induced cardiac toxicity
radiation-induced cystitis
radical hemi-thoracic radiotherapy
radical hysterectomy
radical prostatectomy versus watchful waiting
RADiChol-studie
radioactief jodium
radioembolisatie
radiofrequency localization
radiofrequentie-ablatie
radiogenomics
radiojodium-refractair gedifferentieerd schildkliercarcinoom
radiologic complete response
radiomica
radiomics
radionecrosis
radiosurgery
radiotherapeutic efficacy
radiotherapie
radiotherapy
radiotherapy after BCS
radiotherapy for breast cancer
radiotherapy for childhood cancer
radiotherapy for esophageal cancer
radiotherapy for gynecologic cancers
radiotherapy for oropharyngeal cancer
radiotherapy for prostate cancer
radiotherapy for rectal cancer
radiotherapy or temozolomide
radiotherapy plus ipilimumab
radiotherapy versus temozolomide
radiotherapy-related heuropathic pain
radium 223
radium-223
radon
radotinib
RAI for hyperthyroidism
RAINBOW-studie
RAINFALL study
ralimetinib
raloxifeen
ramucirumab
ramucirumab plus osimertinib
RANGE study
RANGE-studie
RAPID trial
RAPIDO trial
rare cancers
rare CNS tumors
rare T cell lymphomas
rare versus common genetic variants
RARECAREnet
RAS alterations
RAS BRAF-wt metastatic colorectal cancer
RAS mutant unresectable CLM
RAS mutated MGMT methylated mCRC
RAS wild-type metastatic colorectal cancer
RAS wildtype metastatic colorectal cancer
RAS-mutant pancreas adenocarcinoma
RAS-mutaties
RASTEN-studie
rate of memory change
rate of occult contralateral nodal disease
rate of secondary sarcoma
rates of cancer and all-cause mortality
RCC
RCC at intermediate or high risk of relapse
RCM
RD
re-biopsy after first-line treatment
re-excisie
re-testing predictive biomarkers in surgical specimens
REACH-2 study
REACH2 trial
REACH3 study
REACHIN study
ReACT study
readministration of anti-PD-1 or anti-PD-L1 after irAE
readmission
real world effectiveness of nivolumab after systemic therapy
real world outcomes
real-world data
real-world data model
real-world effectivenss for prevemtion of high-grade vulvovaginal lesions
real-world evaluation
real-world outcomes
real-world outcomes of ICIs for cancer
real-world outcomes of neoadjuvant endocrine therapy
real-world QOL with first-line nab-paclitaxel and gemcitabine for mPaC
real-world survival
real-world treatment and survival
real-world use
real-world use of EGFR TKIs
rEC
receptor conversion in breast cancer metastases
receptor discordance between primary tumor and brain metastases
receptor status conversion following neoadjuvant chemotherapy
receptorstatusverandering
recidief
recidiefrisico
recidiefrisico ER-positief mammacarcinoom
recidiverend multipel myeloom
recidiverend of refractair ALL
recidiverend of refractair mantelcellymfoom
recidiverend of refractair multipel myeloom
recidiverend refractair mantelcellymfoom
recidiverend refractair multipel myeloom
recidiverend refractair PCNSL
recidiverende beroerte
recidiverende ER-positieve borstkanker
RECIST
recombinant erythropoietin-refractory anemia
recombinant human granulocyte colony-stimulating factor
recombinant poliovirus for recurrent glioblastoma
recombinant zoster vaccine
recommended definition
RECORD-2
recovery of ovarian function
rectal cancer
rectal cancer in elderly patients
rectumcarcinoom
rectumccarcinoom
rectumkanker
recurrence
recurrence in nipple-areola complex
recurrence of breast cancer
recurrence patterns
recurrence patterns after RT for brain metastases
recurrence predictive model